<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Med</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Mol. Med</journal-id><journal-id journal-id-type="publisher-id">IJMM</journal-id><journal-title-group><journal-title>International Journal of Molecular Medicine</journal-title></journal-title-group><issn pub-type="ppub">1107-3756</issn><issn pub-type="epub">1791-244X</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6414175</article-id><article-id pub-id-type="doi">10.3892/ijmm.2019.4098</article-id><article-id pub-id-type="publisher-id">ijmm-43-04-1789</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>All-<italic>trans</italic> retinoic acid alters the expression of the tight junction proteins Claudin-1 and -4 and epidermal barrier function-associated genes in the epidermis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jing</given-names></name></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Qianying</given-names></name></contrib><contrib contrib-type="author"><name><surname>Geng</surname><given-names>Songmei</given-names></name><xref ref-type="corresp" rid="c1-ijmm-43-04-1789"/></contrib><aff id="af1-ijmm-43-04-1789">Department of Dermatology, Northwest Hospital, Xi&#x02019;an Jiaotong University, Xi&#x02019;an, Shaanxi 710004, P.R. China</aff></contrib-group><author-notes><corresp id="c1-ijmm-43-04-1789">Correspondence to: Dr Songmei Geng, Department of Dermatology, Northwest Hospital, Xi&#x02019;an Jiaotong University, 157 Xi Wu Road, Xi&#x02019;an, Shaanxi 710004, P.R. China, E-mail: <email>gsm312@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>15</day><month>2</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>2</month><year>2019</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>43</volume><issue>4</issue><fpage>1789</fpage><lpage>1805</lpage><history><date date-type="received"><day>12</day><month>9</month><year>2018</year></date><date date-type="accepted"><day>12</day><month>2</month><year>2019</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Li et al.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><p>All-<italic>trans</italic> retinoic acid (ATRA) regulates skin cell proliferation and differentiation. ATRA is widely used in the treatment of skin diseases, but results in irritation, dryness and peeling, possibly due to an impaired skin barrier, although the exact mechanisms are unclear. The present study established an ATRA-associated dermatitis mouse model (n=32) in order to examine the molecular mechanisms of skin barrier impairment by ATRA. Changes in epidermal morphology and structure were observed using histological examination and transmission electron microscopy (TEM). Gene expression was analyzed by microarray chip assay. Histology and TEM demonstrated pronounced epidermal hyperproliferation and parakeratosis upon ATRA application. The stratum corneum layer displayed abnormal lipid droplets and cell-cell junctions, suggesting alterations in lipid metabolism and dysfunctional cell junctions. Gene expression profiling revealed that factors associated with epidermal barrier function were differentially expressed by ATRA, including those associated with tight junctions (TJs), cornified envelopes, lipids, proteases, protease inhibitors and transcription factors. In the mouse epidermis, Claudin-1 and -4 are proteins involved in TJs and have key roles in epidermal barrier function. ATRA reduced the expression and altered the localization of Claudin-1 in HaCaT immortalized keratinocytes and the mouse epidermis, which likely leads to the disruption of the epidermal barrier. By contrast, Claudin-4 was upregulated in HaCaT cells and the mouse epidermis following treatment with ATRA. In conclusion, ATRA exerts a dual effect on epidermal barrier genes: It downregulates the expression of Claudin-1 and upregulates the expression of Claudin-4. Claudin-4 upregulation may be a compensatory response for the disrupted barrier function caused by Claudin-1 downregulation.</p></abstract><kwd-group><kwd>ATRA</kwd><kwd>skin irritation</kwd><kwd>TJ</kwd><kwd>barrier function</kwd><kwd>Claudin-1</kwd><kwd>Claudin-4</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>All-<italic>trans</italic> retinoic acid (ATRA) exerts essential roles in reproduction, embryogenesis, cell proliferation, differentiation and apoptosis (<xref rid="b1-ijmm-43-04-1789" ref-type="bibr">1</xref>,<xref rid="b2-ijmm-43-04-1789" ref-type="bibr">2</xref>). ATRA also regulates skin function and is widely used for the treatment of skin diseases such as acne, psoriasis, ichthyosis and skin cancer (<xref rid="b3-ijmm-43-04-1789" ref-type="bibr">3</xref>-<xref rid="b5-ijmm-43-04-1789" ref-type="bibr">5</xref>), but its clinical application is limited by adverse skin reactions, including erythema, scaling, dryness, desquamation and vessel dilation. These reactions are potentially associated with epidermal barrier dysfunction (<xref rid="b6-ijmm-43-04-1789" ref-type="bibr">6</xref>), but the mechanisms are largely unknown.</p><p>Tight junctions (TJs) in epithelial and endothelial tissues have been well studied, and a previous study suggested that the TJs of the stratum granulosum (SG) are responsible for the protective function of epithelial tissues (<xref rid="b7-ijmm-43-04-1789" ref-type="bibr">7</xref>). TJs consist of transmembrane Claudins, adherent junction (AJ) molecules, occludin, plaque proteins (e.g. zonula occludens-1, -2 and -3, and multiple PDZ domain protein), and cell polarity complex proteins [e.g. the protein kinase C &#x003b9;-type/partitioning defective 3 homolog (Par3)/Par6 complex] (<xref rid="b8-ijmm-43-04-1789" ref-type="bibr">8</xref>). Claudins contain two extracellular loops (cytoplasmic C- and N-terminal) and four transmembrane domains (<xref rid="b9-ijmm-43-04-1789" ref-type="bibr">9</xref>,<xref rid="b10-ijmm-43-04-1789" ref-type="bibr">10</xref>). Claudins-1, -2, -4 and -6 are essential for TJ formation and are involved in the barrier to paracellular transport (<xref rid="b9-ijmm-43-04-1789" ref-type="bibr">9</xref>,<xref rid="b11-ijmm-43-04-1789" ref-type="bibr">11</xref>-<xref rid="b14-ijmm-43-04-1789" ref-type="bibr">14</xref>). The roles of Claudins in barrier function have been addressed in epithelial cell cultures and Claudin-knockout/transgenic mice (<xref rid="b15-ijmm-43-04-1789" ref-type="bibr">15</xref>,<xref rid="b16-ijmm-43-04-1789" ref-type="bibr">16</xref>). Claudin-1 and -4 are concentrated in TJs (<xref rid="b17-ijmm-43-04-1789" ref-type="bibr">17</xref>). Continuous Claudin-based TJs are present in the epidermis and these particular TJs are crucial for the barrier function of mammalian skin (<xref rid="b17-ijmm-43-04-1789" ref-type="bibr">17</xref>). In addition, Claudin-1 and -4 are involved in the pathogenesis of skin lesions (<xref rid="b18-ijmm-43-04-1789" ref-type="bibr">18</xref>-<xref rid="b20-ijmm-43-04-1789" ref-type="bibr">20</xref>). How Claudin-1 and -4 are regulated in response to ATRA is largely unknown.</p><p>To understand the molecular basis of ATRA-induced barrier dysfunction, a gene expression array was used to observe the differential gene expression in mouse skin and HaCaT cells following treatment with ATRA. Using a mouse model and a gene expression array, it was demonstrated that ATRA does, in fact, alter the structure of TJs in mouse skin. Therefore, the hypothesis was that Claudins possibly exert an essential role in barrier dysfunction during ATRA-induced skin irritation. The present study aimed to investigate the molecular mechanisms of barrier dysfunction during ATRA-induced skin irritation.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Animals</title><p>Male BALB/c mice (n=32; 8 weeks of age; weight, ~25 g) were obtained from Xi&#x02019;an Jiaotong University Animal Center (Xi&#x02019;an, China). The mice were fed standard chow and had access to water <italic>ad libitum</italic>, and were caged in a controlled environment (12 h light/dark cycle; temperature, 20-25&#x000b0;C; humidity, 45-55%). The mice were acclimatized for 3 days prior to any experiments. All experimental procedures were performed in accordance with the &#x02018;Principles of Laboratory Animal Care&#x02019; (NIH) and with the approval of the laboratory animal care committee of Xi&#x02019;an Jiaotong University (no. XJTULAC2017-733).</p></sec><sec><title>Animal treatment</title><p>The skin on the backs of the mice was shaved using an electric shaver. The mice were divided into two group: i) Treated with topical 0.1% ATRA cream (Chongqing Winbond Pharmaceutical Co., Ltd., Chongqing, China) twice a day; and ii) treated with an oil/water cream (vehicle control) twice a day. The Psoriasis Area and Severity Index (PASI) scoring system was used to assess the severity of inflammation on the back skin of the mice (<xref rid="b21-ijmm-43-04-1789" ref-type="bibr">21</xref>). The PASI is widely used in clinical practice. Erythema, scales and thickening are scored as follows: 0, absent; 1, slight; 2, mild; 3, obvious; and 4, very obvious. The sum of the scores of these three factors is an indicator of the severity of inflammation (score of 0-12).</p><p>After 5 days of treatment, the mice were anesthetized using pentobarbital at 50 mg/kg. The skin from the backs of the mice, including the dermis and subcutaneous tissues, was removed. The skin was washed with pre-cooled PBS, excess fat was removed, and the specimens were placed in liquid nitrogen for RNA extraction. Subsequently, the mice were sacrificed by cervical dislocation.</p></sec><sec><title>Histological and ultrastructural analysis</title><p>ATRA-treated and untreated mouse dorsal skin specimens (1&#x000d7;1.5 cm) were fixed in 4% paraformaldehyde for 24 h at 4&#x000b0;C, dehydrated and embedded in paraffin. The samples were sectioned at 7 <italic>&#x000b5;</italic>m and stained with hematoxylin for 5 min and eosin for 2 min at room temperature. The epidermal thickness, parakeratosis, spongiosis and degree of inflammation were evaluated. Spongiosis (presence of widened intracellular spaces between epidermal keratinocytes) and inflammation were evaluated on a scale of 0-4. Epidermal thickness and spongy edema were measured using the built-in measurement tool in the software ndp.view2 (Hamamatsu Photonics K.K., Hamamatsu, Japan; <ext-link ext-link-type="uri" xlink:href="https://www.hamamatsu.com/jp/en/product/type/U12388-01.html">https://www.hamamatsu.com/jp/en/product/type/U12388-01.html</ext-link>; version 2.7). The expanded capillaries were counted at high magnification (&#x000d7;200) in 10 randomly selected fields under an Olympus BX51 light microscope equipped with a DP70 digital camera (Olympus Corporation, Tokyo, Japan). Incomplete keratinization was assessed as present or absent (<xref rid="b22-ijmm-43-04-1789" ref-type="bibr">22</xref>).</p><p>The specimens were cut into 1-cm blocks and dipped in ice-cold sodium cacodylate buffer solution containing 2.5% glutaraldehyde at 4&#x000b0;C for 24 h. The blocks were washed three times and treated with 1% osmium tetroxide at 4&#x000b0;C for 1 h. The samples were dehydrated using an ethanol series and embedded in Epon 812. Ultra-thin sections were stained with lead citrate for 10 min and uranyl acetate for 30 min at room temperature. Ultrastructural changes were observed by transmission electron microscopy (TEM) using a H7650 microscope (Hitachi, Ltd., Tokyo, Japan).</p></sec><sec><title>Cell culture and treatment</title><p>HaCaT cells (immortalized keratinocytes) were obtained from the Fourth Military Medical University (Shan&#x02019;xi, China) and grown in RPMI-1640 (GE Healthcare, Chicago, IL, USA) with 10% fetal bovine serum (Life Technologies; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% penicillin-streptomycin (GE Healthcare). Short tandem repeat profiling was performed by Shanghai Zhong Qiao Xin Zhou Biotechnology Co., Ltd. (Shanghai, China) to validate the cell line. The cells were subcultured following dissociation with 0.25% trypsin/0.05% EDTA (1:1) and passaged at a ratio of 1:4 every 3 days.</p><p>HaCaT cells (5,000 cells/well) were incubated in 96-well plates for 48 h and treated by different concentrations (0.1, 0.5, 1, 5 and 10 <italic>&#x000b5;</italic>M) of ATRA at 37&#x000b0;C for a further 36 h. A volume of 20 <italic>&#x000b5;</italic>l MTT solution (5 mg/ml) was added to each well and the culture continued for 4 h. Subsequently, the medium was removed, and 150ul dimethyl sulfoxide (DMSO) was added to each well. The light absorption value of each well was measured at optical density 490 nm (570 nm) with a micro-plate reader. Following determination of the half-maximal inhibitory concentration using different concentrations of ATRA (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), HaCaT cells were incubated with or without 1 <italic>&#x000b5;</italic>M ATRA for 36 h at 37&#x000b0;C, which was chosen for use in the subsequent experiments. Stock solutions of ATRA (0.01 M) were prepared in DMSO, stored in the dark at &#x02212;20&#x000b0;C, and further diluted with RPMI-1640. The concentration of DMSO was 1&#x02030;.</p></sec><sec><title>Microarray analysis</title><p>Microarray analysis was used primarily to identify candidates that were later confirmed via reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and/or immunohistochemistry. The gene expression profiles in the skin of mice and in HaCaT cells treated or untreated with ATRA were compared using NimbleGen Gene Expression analysis (Nimblegen Systems Inc., Madison, WI, USA). The ds-cDNA samples were washed and labeled according to the Nimblegen Gene Expression Analysis protocol (Nimblegen Systems Inc.). A NanoDrop ND-1000 was used to quantify the cDNA following purification. Cy3 labeling was conducted using the NimbleGen One-Color DNA labeling kit (NimbleGen Systems, Inc.), according to the manufacturer&#x02019;s protocol. Subsequently, 100 U Klenow fragment (New England Biolabs, Inc., Ipswich, MA, USA) and 100 pmol deoxynucleoside triphosphates were added and incubated at 37&#x000b0;C for 2 h. One-tenth volume of 0.5 M EDTA was added to stop the reaction. The labeled ds-cDNA was purified using isopropanol/ethanol precipitation. The microarrays were immersed in the NimbleGen hybridization buffer/hybridization component A, which was supplemented with 4 <italic>&#x000b5;</italic>g ds-cDNA with Cy3 labeling. The reaction system was kept in a hybridization chamber (Nimblegen Systems, Inc.) at 42&#x000b0;C for 4 h. The NimbleGen Wash Buffer kit (Nimblegen Systems, Inc.) was used to wash the microarrays in an environment without ozone. The Axon GenePix 4000B microarray scanner was used to scan the microarrays.</p></sec><sec><title>RT-qPCR</title><p>The RNAeasy Midi kit (Qiagen AB, Sollentuna, Sweden) was used to isolate the total mRNA, according to the manufacturer&#x02019;s protocol. RNA (1 <italic>&#x000b5;</italic>g) was added in a 20-<italic>&#x000b5;</italic>l reaction system (PrimeScript RT Reagent Kit; Takara, Otsu, Japan) at 37&#x000b0;C for 15 min and 85&#x000b0;C for 5 sec for cDNA synthesis. The SYBR Premix Ex Taq II amplification kit (Perfect Real Time; Takara Biotechnology Co., Ltd., Dalian, China) was used for qPCR on a Bio-Rad IQ5 System (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The conditions were: i) 95&#x000b0;C denaturation for 10 min; and ii) 40 cycles at 95&#x000b0;C for 10 sec and 60&#x000b0;C for 30 sec. The primers are listed in <xref rid="tI-ijmm-43-04-1789" ref-type="table">Table I</xref>. &#x003b2;-actin was used for normalization. The results were analyzed using the IQ5 software (version 2.5). Gene expression levels were calculated using the 2<sup>&#x02212;&#x00394;&#x00394;Cq</sup> method (<xref rid="b23-ijmm-43-04-1789" ref-type="bibr">23</xref>).</p></sec><sec><title>Western blotting</title><p>ATRA-treated and untreated HaCaT cells were lysed in radioimmunoprecipitation assay buffer [150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 0.5% deoxycholate, 0.1% SDS, 1% Nonidet P-40 and protease inhibitor cocktail; Sigma-Aldrich; Merck KGaA] at 4&#x000b0;C for 1 h. Protein concentration was measured using a bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology, Haimen, China). Equal amounts of proteins (30 <italic>&#x000b5;</italic>g) were separated on 12% SDS-PAGE gels and transferred to PVDF membranes (EMD Millipore, Billerica, MA, USA). TBS buffer containing Tween-20 (TBST) and 5% non-fat milk was used to block non-specific binding at room temperature for 2 h. Following blocking, primary antibodies were incubated overnight at 4&#x000b0;C: Rabbit anti-human Claudin-1 (cat. no. 13050-1-AP; ProteinTech Group, Inc., Chicago, IL, USA; 1:200), goat anti-human Claudin-4 (cat. no. 17664; Santa Cruz Biotechnology, Inc., Dallas, TX, USA; 1:200) and mouse anti-human &#x003b2;-actin (cat. no. 47778; Santa Cruz Biotechnology, Inc.; 1:1,000). The membranes were washed three times with TBST for 5 min. Horseradish peroxidase (HRP)-conjugated Affinipure Rabbit Anti-Goat IgG (H+L) (cat. no. SA00001-2; ProteinTech Group, Inc.; 1:3,000), HRP-conjugated Affinipure Goat Anti-Mouse IgG (H+L) (cat. no. SA00001-1; ProteinTech Group, Inc.; 1:3,000) and HRP-conjugated Affinipure Donkey Anti-Goat IgG (H+L) (cat. no. SA00001-3; ProteinTech Group, Inc.; 1:4,000) were incubated for 1 h at 37&#x000b0;C prior to visualization with enhanced chemiluminescence (Amersham; GE Healthcare). Densitometry was used to quantify the signal intensities using Quantity One 4.5 software (Bio-Rad Laboratories, Inc.). All measurements were performed in triplicates from three independent experiments.</p></sec><sec><title>Immunofluorescence</title><p>HaCaT cells and cryostat sections (4 <italic>&#x000b5;</italic>m) of skin from ATRA-treated and untreated mice were fixed in ice-cold 4% paraformaldehyde in PBS for 30 min. Non-specific binding was blocked with 10% normal goat serum (OriGene Technologies, Inc., Beijing, China) for 20 min at 37&#x000b0;C. Goat anti-human Claudin-4 (1:50) and rabbit anti-human Claudin-1 antibodies (1:50) were incubated overnight at 4&#x000b0;C. PBS was used as a negative control. The sections were washed twice for 5 min in PBS. Alexa Fluor 594-labeled secondary antibodies (cat. nos. A32758 and A32740; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA; 1:200) were incubated for 1 h at room temperature and revealed using DAPI (1:5,000 in PBS) for 2 min at room temperature. A laser scanning confocal microscope (LSM510; Zeiss AG, Oberkochen, Germany) was used to capture images of the cells (&#x000d7;200 magnification).</p></sec><sec><title>Statistical analysis</title><p>All statistical analyses were conducted using SPSS 16.0 (SPSS, Inc., Chicago, IL, USA). Data are expressed as the mean &#x000b1; standard deviation. All measurements were performed in triplicate from three independent experiments. The distribution was tested for normality using the Kolmogorov-Smirnov test. Statistical significance was evaluated by independent sample t-test for normally distributed data and using the Mann-Whitney U test for non-normally distributed data. P&#x0003c;0.05 was considered to indicate a statistically significant difference.</p><p>For the microarray data, the NimbleScan software (version 2.5; NimbleGen Systems, Inc.) was used to conduct grid alignment and analyze the expression profiles. The Robust Multichip Average (RMA) algorithm and quantile normalization in NimbleScan software were applied to the normalized expression data. The gene levels were inputted into the Agilent GeneSpring software (version 12.0; Agilent Technologies, Inc., Santa Clara, CA, USA). Fold-change filtering was applied for the identification of genes with differential expression levels. The threshold was set at-fold-change &#x02265;2.0. The Agilent GeneSpring GX software (version 12.0; Agilent Technologies, Inc.) was used to conduct hierarchical clustering. The roles of the differentially expressed genes were determined using Gene Ontology (GO; <ext-link ext-link-type="uri" xlink:href="http://www.geneontology.org">www.geneontology.org</ext-link>) and pathway analyses (<ext-link ext-link-type="uri" xlink:href="https://www.genome.jp/kegg">https://www.genome.jp/kegg</ext-link>) conducted on the basis of the standard enrichment computation method, and using Fisher&#x02019;s exact test to determine whether the amount of overlaps between the GO annotation list and the list of differentially expressed genes was significant. P&#x02264;0.05 indicated that the GO term enrichment was statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Topical ATRA induces histological alterations in the skin of treated mice</title><p>After 5 days of treatment, no marked alterations were detected in the control skin. Circumscribed erythema occurred after 3 days of ATRA application (n=6), with fine flat scales covering the surface of the erythema that peaked at 5 days (<xref rid="f1-ijmm-43-04-1789" ref-type="fig">Fig. 1</xref>). Hematoxylin and eosin staining of ATRA-treated skin demonstrated crust, focal parakeratosis, hyperproliferation and intercellular edema of the stratum spinosum (<xref rid="f2-ijmm-43-04-1789" ref-type="fig">Fig. 2A</xref>). In the ATRA-treated dermis, large amounts of inflammatory cell infiltration and capillary dilation were observed (<xref rid="f2-ijmm-43-04-1789" ref-type="fig">Fig. 2A</xref>). Epidermal thickness was 2.5 times higher following ATRA intervention compared with that of the control group (P&#x0003c;0.0001), in addition to increases in parakeratosis (P&#x0003c;0.001) and spongiosis (P&#x0003c;0.002). In the dermis, perivascular lymphocytic infiltration (P&#x0003c;0.002) and telangiectasia (P&#x0003c;0.002) were observed in the dermal papilla and in the superficial layer (<xref rid="f2-ijmm-43-04-1789" ref-type="fig">Fig. 2B</xref>).</p></sec><sec><title>ATRA treatment causes ultrastructural abnormalities in the epidermis</title><p>Compared with control skin, keratohyalin granules were decreased in number in the SG (n=3; <xref rid="f3-ijmm-43-04-1789" ref-type="fig">Fig. 3A</xref>). TEM also demonstrated that the keratinocyte cytoskeleton was damaged by ATRA and that the cytoskeletal network disappeared in the local upper stratum corneum (<xref rid="f3-ijmm-43-04-1789" ref-type="fig">Fig. 3A</xref>). In the upper stratum corneum, multiple lipid droplets were observed in the cytoplasm of corneocytes in the ATRA-treated skin (<xref rid="f3-ijmm-43-04-1789" ref-type="fig">Fig. 3B</xref>). In the epidermis of ATRA-treated skin, TEM revealed a disordered arrangement of stratum spinosum cells, in addition to the appearance of significantly larger nucleoli and wider intercellular spaces (<xref rid="f3-ijmm-43-04-1789" ref-type="fig">Fig. 3B</xref>). Desmosomes were decreased and disordered in ATRA-treated skin (<xref rid="f3-ijmm-43-04-1789" ref-type="fig">Fig. 3C</xref>). Quantitative analysis of keratohyalin granules, lipid droplets and desmosomes is presented in <xref rid="f3-ijmm-43-04-1789" ref-type="fig">Fig. 3D</xref>.</p></sec><sec><title>Gene expression profiling reveals dysregulation of epidermal barrier-associated genes in the mouse epidermis and HaCaT cells treated with ATRA</title><p>With the aim of improving the understanding of the molecular mechanisms of ATRA-induced barrier dysfunction, gene expression array analysis (n=1) was used to identify candidate genes for barrier function in the mouse skin and HaCaT cells. There were 897 upregulated and 1,087 downregulated genes following treatment with ATRA in the mouse epidermis. Similarly, there were 1,220 upregulated and 905 downregulated genes following treatment with ATRA in HaCaT cells. The genes involved in epidermal barrier function were revealed by gene expression analyses and are presented in <xref rid="tII-ijmm-43-04-1789" ref-type="table">Tables II</xref>&#x02013;<xref rid="tIII-ijmm-43-04-1789" ref-type="table"/><xref rid="tIV-ijmm-43-04-1789" ref-type="table"/><xref rid="tV-ijmm-43-04-1789" ref-type="table">V</xref>. The downregulated epidermal barrier-associated genes following treatment with ATRA in the mouse skin included genes involved in &#x02018;cornified envelope components&#x02019;, &#x02018;intermediate filament&#x02019;, &#x02018;lipid metabolic process&#x02019;, &#x02018;gap junction&#x02019;, &#x02018;tight junction&#x02019; and &#x02018;desmosome&#x02019; (<xref rid="tII-ijmm-43-04-1789" ref-type="table">Table II</xref>). The upregulated epidermal barrier-associated genes following treatment with ATRA in mouse skin included genes involved in &#x02018;cornified envelope components&#x02019;, &#x02018;serine protease and protease inhibitors&#x02019;, &#x02018;lipid metabolic process&#x02019;, &#x02018;tight junction&#x02019; and &#x02018;transcriptional factors&#x02019; (<xref rid="tIII-ijmm-43-04-1789" ref-type="table">Table III</xref>). The downregulated epidermal barrier-associated genes following treatment with ATRA in HaCaT cells included genes involved in &#x02018;intermediate filament&#x02019;, &#x02018;proteases and protease inhibitors&#x02019; and &#x02018;tight junction&#x02019; (<xref rid="tIV-ijmm-43-04-1789" ref-type="table">Table IV</xref>). The upregulated epidermal barrier-associated genes following treatment with ATRA in HaCaT cells included genes involved in &#x02018;intermediate filament&#x02019;, &#x02018;proteases and protease inhibitors&#x02019; and &#x02018;tight junction&#x02019; (<xref rid="tV-ijmm-43-04-1789" ref-type="table">Table V</xref>).</p><p>The pathway analyses demonstrated that differentially expressed genes were significantly associated with AJs, TJs and focal adhesion in ATRA-treated epidermal tissues. The top ten pathways of up- and downregulated differentially expressed genes are presented in <xref rid="f4-ijmm-43-04-1789" ref-type="fig">Fig. 4A and B</xref>, respectively. The top ten three GO-fold enrichment of differentially expressed genes revealed significant downregulation of epidermal barrier function-associated processes, including &#x02018;regulation of keratinocyte differentiation&#x02019;, &#x02018;keratin filament&#x02019; and &#x02018;gap junction&#x02019; channel activity (<xref rid="f4-ijmm-43-04-1789" ref-type="fig">Fig. 4C-H</xref>). In ATRA-treated epidermal tissues, a series of dysregulated genes associated with the epidermal differentiation complex (EDC) were observed, which included small proline-rich region proteins (SPRRs), filaggrin (FLG), loricrin (LOR) and the S100 gene family. These proteins are essential for the formation of the cell envelope during terminal differentiation. A number of these genes were members of the SPRR family: <italic>SPRR4</italic> (&#x02212;2.67-fold), <italic>SPRR2J</italic> (+2.38-fold) and <italic>SPRR2G</italic> (+3.57-fold). The remainder were part of the S100 gene family: <italic>S100A8</italic> (+3.31-fold) <italic>S100A9</italic> (+3.81-fold) and <italic>FLG</italic> (&#x02212;2.13-fold) (<xref rid="tII-ijmm-43-04-1789" ref-type="table">Tables II</xref> and <xref rid="tIII-ijmm-43-04-1789" ref-type="table">III</xref>). During keratinocyte differentiation, the late cornified envelope protein (LCE) was induced and had similar functions to the functions of the SPRR family (cross-linking proteins) in the CE. <italic>LCE1M</italic> (6.64-fold) was downregulated, while <italic>LCE3C</italic> (5.35-fold) and <italic>LCE3B</italic> (3.17-fold) were upregulated (<xref rid="tII-ijmm-43-04-1789" ref-type="table">Tables II</xref> and <xref rid="tIII-ijmm-43-04-1789" ref-type="table">III</xref>). Nevertheless, no notable abnormalities were observed in the above genes in HaCaT cells. In ATRA-treated epidermal tissues and HaCaT cells, marked dysregulation of numerous keratins and keratin-associated proteins was observed, suggesting abnormal terminal differentiation of keratinocytes upon ATRA treatment. Serine proteases and serine protease inhibitors are involved in the differentiation of keratinocytes and desquamation (<xref rid="b24-ijmm-43-04-1789" ref-type="bibr">24</xref>). In ATRA-treated epidermal tissues and HaCaT cells, the differential expression of serine proteases and serine protease inhibitors was observed. Among them, it was observed that KLK6 and KLK10 were consistently expressed in the mouse chip and HaCaT cells, and all of them were upregulated.</p><p>Genes encoding enzymes associated with lipid metabolism were demonstrated to be induced by ATRA in the mouse epidermis. Compared with the cells, the mice exhibited significant downregulation of a subset of enzymes associated with ceramide, free fatty acids and phospholipid synthesis: i) Sphingomyelin phosphodiesterase 3 (<italic>SMPD3</italic>; -2.15-fold) and sphingomyelin phosphodiesterase 2 (<italic>SMPD2</italic>, -2.10-folds), which catalyze the conversion of sphingolipids to ceramides; ii) epidermal ceramide synthase 5 (<italic>LASS5/Cers5</italic>; -2.82-fold), which catalyzes the synthesis of ceramides; iii) lysophospholipase II (<italic>LYPLA</italic>; -2.00-fold), phospholipase A2 group IIE2 (<italic>PLA2G2E</italic>; -2.60-fold), and phospholipase C eta 2 (<italic>PLCH2</italic>; -2.13-fold), which catalyze free fatty acid formation from phospholipids; and iv) 1-acylglycerol-3-phosphate O-acyltransferase 4 (<italic>AGPAT4</italic>; -3.81-fold) and 1-acylglyc-erol-3-phosphate O-acyltransferase 5 (<italic>AGPAT5</italic>; -3.17-fold), which catalyze the acylation of lysophosphatidic acid into phosphatidic acid. The latter is the primary precursor of all types of glycerolipids. Furthermore, arachidonate lipoxygenase (<italic>ALOX12E</italic>; a member of the epidermis-type LOX family that catalyzes the conversion of polyunsaturated fatty acids into oxygenated products) was downregulated by ATRA. Conversely, the present results also demonstrated upregulation of different isoforms of the aforementioned enzymes (<xref rid="tIII-ijmm-43-04-1789" ref-type="table">Table III</xref>).</p><p>The dysregulation of numerous cell-cell junction-associated genes was observed in ATRA-treated mouse skin. Among these genes were components of TJs (<italic>TJAP1</italic>, <italic>MPP7</italic>, <italic>MARVELD2</italic> and <italic>CLDN2</italic>), gap junctions (<italic>GJA, GJA</italic> and <italic>GJB4</italic>) and desmosomes (<italic>DSG2</italic>). Compared with the mouse skin specimens, only the TJ protein molecules Claudin-4 and occludin were upregulated in the cells.</p></sec><sec><title>ATRA treatment alters the expression and localization of TJs in HaCaT cells</title><p>In ATRA-treated cells, <italic>CLDN1</italic> was downregulated 0.66-fold, while <italic>CLDN4</italic>, <italic>TJP3</italic> and <italic>GJB4</italic> were upregulated 1.82-, 3.63- and 1.92-fold (<xref rid="f5-ijmm-43-04-1789" ref-type="fig">Fig. 5A</xref>). In mice treated with ATRA, <italic>CLDN1</italic> (0.8-fold) and <italic>FLG</italic> (0.61-fold) were downregulated, while <italic>CLDN4</italic> (1.47-fold) and <italic>CLDN2</italic> (2.49-fold) were upregulated (<xref rid="f5-ijmm-43-04-1789" ref-type="fig">Fig. 5B</xref>). Western blot analysis of CLDN4 and CLDN1 revealed similar results to those of the RT-qPCR (<xref rid="f5-ijmm-43-04-1789" ref-type="fig">Fig. 5C</xref>).</p><p>Immunofluorescence revealed that the intensity of Claudin-1 was not only reduced at the cell-cell contact areas, but also appeared to be discontinuous along the cell membranes of HaCaT cells treated with ATRA (<xref rid="f6-ijmm-43-04-1789" ref-type="fig">Fig. 6</xref>). However, Claudin-4 staining was slightly increased and displayed a string-like localization pattern (<xref rid="f6-ijmm-43-04-1789" ref-type="fig">Fig. 6</xref>).</p></sec><sec><title>ATRA alters the expression and localization of TJs in mouse epidermis</title><p>A marked reduction in the staining intensity and localization of Claudin-1 in the upper epidermal layer of skin treated with ATRA was discovered compared with control skin (n=3; <xref rid="f7-ijmm-43-04-1789" ref-type="fig">Fig. 7</xref>). By contrast, Claudin-4 staining was stronger in the ATRA-treated skin compared with control skin (<xref rid="f7-ijmm-43-04-1789" ref-type="fig">Fig. 7</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In the present study, the ATRA-associated dermatitis animal model presented erythema, scaling and dryness of the treated skin, similar to the irritation observed in ATRA-treated human skin (<xref rid="b25-ijmm-43-04-1789" ref-type="bibr">25</xref>,<xref rid="b26-ijmm-43-04-1789" ref-type="bibr">26</xref>), indicating that this animal model is a useful tool to evaluate the effectiveness and side effects of ATRA. Furthermore, treatment with ATRA altered the normal morphology and ultrastructure of the mouse epidermis. Microarray analysis was used, primarily to identify candidates that were later confirmed via RT-qPCR and/or immunohistochemistry.</p><p>In the mouse model of ATRA-stimulated dermatitis, the epidermis of the mice exhibited obvious scales, while histopathology revealed parakeratosis of the epidermis, suggesting that the epidermal differentiation was abnormal, and that the abnormal differentiation of keratinocytes led to an epidermal keratinization envelope. In the mouse gene expression profiles, it was observed that the majority of alterations occurred among EDC genes, including <italic>FLG</italic>, <italic>SPRR4</italic>, <italic>SPRR2J</italic>, <italic>SPRR2G</italic>, <italic>LCE3C</italic>, <italic>LCE3B</italic>, <italic>LCE1M</italic>, <italic>S100A8</italic> and <italic>S100A9</italic>. The proteins encoded by those genes, together with LOR, involucrin, trichohyalin and hornerin, are associated with CE generation via crosslinking of insoluble membranous proteins (<xref rid="b27-ijmm-43-04-1789" ref-type="bibr">27</xref>). Keratinized proteins act as markers of differentiation in the epidermis. In the mice and cells, the abnormal expression of keratins, including <italic>KRT15</italic>, <italic>KRT17</italic> and <italic>KRT14</italic>, and keratin-associated proteins, including <italic>KRT33A</italic>, <italic>KRT33A</italic> and <italic>KRTAP1-3</italic>, was widely observed, further confirming the abnormal terminal differentiation in the epidermis following ATRA treatment.</p><p>Proteases, together with their inhibitors and targets, serve an essential role in desquamation (<xref rid="b24-ijmm-43-04-1789" ref-type="bibr">24</xref>). In the ATRA-treated mouse epidermis and HaCaT cells, the upregulation of tissue kallikreins (<italic>KLK6</italic>, <italic>KLK10</italic>, <italic>KLK12</italic> and <italic>KLK14</italic>) and protease inhibitors (<italic>SERPINE 1</italic> and <italic>SERPINE 2</italic>) was demonstrated. It is noteworthy that KLK6 and KLK10 were upregulated in mice and cells following ATRA treatment, which may be closely associated with the appearance of scales on the mouse skin. Furthermore, alterations in the balance between proteases and protease inhibitors in the skin lead to inflammatory reactions, which causes itching, scaling, redness and other typical clinical symptoms (<xref rid="b28-ijmm-43-04-1789" ref-type="bibr">28</xref>).</p><p>Morphologically, the appearance of profilaggrin is consistent with the formation of keratohyalin granules. The newly-synthesized profilaggrin accumulates in keratohyalin granules with high phosphoric acid and histidine following phosphorylation. The present study demonstrated that the number of keratohyalin granules decreased significantly following ATRA treatment. Therefore, it was speculated that decreases in the number of keratohyalin granules may affect the phosphorylation and accumulation of newly-synthesized profilaggrin, affecting the production of FLG. In addition, a number of factors that are important in controlling FLG expression have been described, such as transcription factors of the AP1 family (Jun and/or Fos), POU-domain proteins, transcription factor p63, and the peroxisome-proliferator-activated-receptor (PPAR) family (<xref rid="b29-ijmm-43-04-1789" ref-type="bibr">29</xref>). Aberrant profilaggrin processing has also been observed in 12R-lipoxygenase (12R-LOX)-deficient mice (<xref rid="b30-ijmm-43-04-1789" ref-type="bibr">30</xref>). In the present study, the gene chip results revealed that PPAR was upregulated and <italic>ALOX12E</italic> was downregulated following ATRA treatment. As expected, the gene chip analysis and RT-qPCR revealed that the expression of <italic>FLG</italic> was downregulated following ATRA treatment in the mouse skin, as supported by Sybert <italic>et al</italic> (<xref rid="b31-ijmm-43-04-1789" ref-type="bibr">31</xref>), who reported that patients with ichthyosis vulgaris displayed a reduction or absence of profilaggrin and FLG along with a morphological reduction in the amount of keratohyalin. Filaggrin is also involved in the production of primary natural moisturizing factors in the stratum corneum (<xref rid="b29-ijmm-43-04-1789" ref-type="bibr">29</xref>). Whether these alterations in expression may affect the expression of FLG and the specific regulatory mechanism requires further investigation.</p><p>Following ATRA treatment, alterations in the ultrastructure of the epidermis were observed under an electron microscope. The images revealed that there were numerous circular vacuolated structures in the stratum corneum, which were similar to the ultrastructure of lipid droplets. Ponec <italic>et al</italic> (<xref rid="b32-ijmm-43-04-1789" ref-type="bibr">32</xref>) studied the lipid and ultrastructure of reconstructed skin models by electron microscopy. Their results indicated that lipid droplets in keratinocytes appeared in all three skin models, but the extent of the lipid droplets varied. The structure of the lipid droplets in their images was consistent with the structure of lipid droplets observed under electron microscopy in the present study. It was also thought that the different levels of lipid droplets in keratinocytes were associated with the hyperproliferative state of reconstructed skin. On the other hand, the epidermal layers of the mice in the present study were increased following ATRA treatment, indicating that there was a degree of proliferation. Therefore, it was speculated that these structures may be lipid droplets. Nevertheless, this is a limitation of the present study.</p><p>The ATRA-treated mouse skin displayed a large number of lipid droplets in certain corneocytes [similar in appearance to the droplets observed by Ponec <italic>et al</italic> (<xref rid="b32-ijmm-43-04-1789" ref-type="bibr">32</xref>)], suggesting that lipid metabolism was abnormal. Gene expression analysis of skin samples from ATRA-treated and control skin demonstrated significant induction of functional proteins associated ceramide, non-esterified fatty acids and phospholipid synthesis. The present study revealed down-regulation of <italic>SMPD3</italic>, <italic>SMPD2</italic> and <italic>LASS5/Cers5</italic>, which catalyze the synthesis of ceramides, suggesting decreased ceramide synthesis in ATRA-treated mice. Conversely, it was observed that ATRA also increased the expression of UDP-glucose ceramide glucosyltransferase (UGCG). Moreover, Amen <italic>et al</italic> (<xref rid="b33-ijmm-43-04-1789" ref-type="bibr">33</xref>) reported that mice with deficiencies in UGCG display an ichthyosis-like skin phenotype and impairment in the differentiation of keratinocytes, which is associated with delayed wound healing.</p><p>Mao-Qiang <italic>et al</italic> (<xref rid="b34-ijmm-43-04-1789" ref-type="bibr">34</xref>) demonstrated that inhibiting <italic>PLA2</italic> resulted in a defective extracellular lipid membrane and impaired homeostasis in the permeability barrier (<xref rid="b34-ijmm-43-04-1789" ref-type="bibr">34</xref>). In the present study, ATRA not only downregulated <italic>PLA2G2E</italic> and other phospholipases including <italic>PLCH2,</italic> but also upregulated <italic>PLA2G4E</italic>, <italic>LYPLA</italic> and <italic>DEG</italic>. Lu <italic>et al</italic> (<xref rid="b35-ijmm-43-04-1789" ref-type="bibr">35</xref>) demonstrated that the transcription levels of AGPAT-1, -2 and -3 were rapidly increased by ATRA. The present gene expression analysis of ATRA-treated skin revealed a marked reduction in the levels of <italic>AGPAT4</italic> and <italic>AGPAT5</italic>.</p><p>Previously, lipoxygenases (LOXs) were reported to exert essential roles in regulating epithelial proliferation and/or differentiation, maintaining the permeability barrier, skin inflammation and wound healing (<xref rid="b36-ijmm-43-04-1789" ref-type="bibr">36</xref>). In the present study, no marked alterations in the protein levels of <italic>eLOX-3</italic> and <italic>12R-LOX</italic> in ATRA-treated skin were detected, but ATRA-treatment significantly downregulated <italic>ALOX12E</italic>, which may have a role in regulating keratinocyte differentiation (<xref rid="b37-ijmm-43-04-1789" ref-type="bibr">37</xref>).</p><p>TEM analysis of the mouse skin revealed an increase in the intercellular space, suggesting that the keratinocytes of the mice may have had abnormalities in the TJs. TJs function as a paracellular barrier beneath the stratum corneum (<xref rid="b38-ijmm-43-04-1789" ref-type="bibr">38</xref>). In the present study, Claudin-1 was decreased, but Claudin-4 was increased following ATRA-treatment in HaCaT cells and the mouse epidermis. Claudin-1-knockout mice exhibit increased epidermal permeability, severe water loss and skin wrinkling, and succumb within 24 h after birth (<xref rid="b17-ijmm-43-04-1789" ref-type="bibr">17</xref>). Downregulation of Claudin-1 results in decreased transepithelial electrical resistance (<xref rid="b39-ijmm-43-04-1789" ref-type="bibr">39</xref>). In addition, patients with atopic dermatitis exhibit low levels of Claudin-1 expression (<xref rid="b40-ijmm-43-04-1789" ref-type="bibr">40</xref>). Nevertheless, a previous <italic>in vitro</italic> study of cultured keratinocytes uncovered barrier defects resulting from knocking down Claudin-4 (<xref rid="b41-ijmm-43-04-1789" ref-type="bibr">41</xref>). The present study revealed that the expression of Claudin-4 was increased following ATRA treatment in HaCaT cells and the mouse epidermis, as previously observed in the oral mucosa (<xref rid="b14-ijmm-43-04-1789" ref-type="bibr">14</xref>). Nevertheless, significant upregulation of Claudin-4 was observed in the non-lesional skin of patients with atopic dermatitis, which may indicate a compensatory response to disrupted barrier function caused by Claudin-1 downregulation that leads to the upregulation of other Claudins (<xref rid="b18-ijmm-43-04-1789" ref-type="bibr">18</xref>,<xref rid="b42-ijmm-43-04-1789" ref-type="bibr">42</xref>). Therefore, downregulated Claudin-1 and the alteration of its localization in HaCaT cells and the mouse epidermis was likely responsible, at least in part, for the observed disruption of TJ barrier function following ATRA treatment.</p><p>It was observed that Claudin-2 mRNA was upregulated 2.5-fold. Telgenhoff <italic>et al</italic> (<xref rid="b43-ijmm-43-04-1789" ref-type="bibr">43</xref>) studied the regulation of Claudin-2 mRNA and protein expression by ATRA in human keratinocytes, and discovered that ATRA increases the expression of Claudin-2 in keratinocytes in a dose-dependent manner. In addition, Claudin-2 is highly expressed in the TJs of mouse renal proximal tubules, which possess a leaky epithelium whose unique permeability properties underlie their high rate of NaCl reabsorption (<xref rid="b43-ijmm-43-04-1789" ref-type="bibr">43</xref>,<xref rid="b44-ijmm-43-04-1789" ref-type="bibr">44</xref>). On the other hand, the Cldn2-KO mice display a normal appearance, activity, growth and behavior, with no abnormalities in the epidermal barrier (<xref rid="b44-ijmm-43-04-1789" ref-type="bibr">44</xref>); therefore, it was not included in the present study as a candidate gene due to funding limitations, but it may be considered in future studies.</p><p>Notably, certain differences were observed between the <italic>in vivo</italic> and the <italic>in vitro</italic> experiments. The possible causes include the following: i) HaCaT cells are human-derived immortalized keratin-forming cells, while the skin tissues were derived from mice, thus the two are different in species; ii) cells growing <italic>in vitro</italic> and <italic>in vivo</italic> are not completely analogous; and iii) the doses of ATRA <italic>in vivo</italic> and <italic>in vitro</italic> were different. In addition, the present study is limited since it focused primarily on Claudin-1 and -4, and additional studies are required to assess the exact contribution to ATRA-induced dermatitis of all the identified differentially expressed genes. The microarray experiment would ideally have been performed in multiple samples, but research funding was very limited; thus, there was only one sample per group, which is a limitation. Nevertheless, the microarray experiment only provides an idea of the potential genes that may be examined in future studies. Subsequent experiments <italic>in vivo</italic> and <italic>in vitro</italic> will be performed to confirm the results.</p><p>In conclusion, the results suggest that ATRA disrupts the normal morphology and ultrastructure of the mouse epidermis and exerts an essential role in the function of the epidermal barrier. Gene expression analyses revealed numerous dysregulated genes associated with the synthesis/generation of transcription factors, protease inhibitors, proteases, junctional proteins, lipids, corneocytes and cornified envelopes. ATRA not only alters the expression of Claudin-1 and -4, but also alters their localization in HaCaT cells and the murine epidermis. ATRA exerts a dual effect on epidermal barrier genes: It downregulates the expression of Claudin-1 and upregulates the expression of Claudin-4. Claudin-4 upregulation may be a compensatory response for the disrupted barrier function caused by Claudin-1 downregulation.</p></sec></body><back><ack><title>Acknowledgments</title><p>Not applicable.</p></ack><sec sec-type="other"><title>Funding</title><p>The present study was supported by the National Natural Science Foundation of China (grant no. 81171490) and the Fundamental Research Funds for the Central Universities (grant no. PY3A0241001016).</p></sec><sec sec-type="materials"><title>Availability of data and materials</title><p>The datasets generated and/or analyzed during the current study are available in the GEO repository (GSE124183): <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE124183">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE124183</ext-link>.</p></sec><sec sec-type="other"><title>Authors&#x02019; contributions</title><p>SG and JL designed the experiments. JL conducted the experiments, performed the statistical analysis and drafted the manuscript. QL performed the statistical analysis. All authors read and approved the final manuscript.</p></sec><sec sec-type="other"><title>Ethics approval and consent to participate</title><p>All experimental procedures were performed in accordance with the &#x02018;Principles of Laboratory Animal Care&#x02019; (National Institutes of Health) and the guidelines of the laboratory animal care committee of Xi&#x02019;an Jiaotong University (no. XJTULAC2017-733).</p></sec><sec sec-type="other"><title>Patient consent for publication</title><p>Not applicable.</p></sec><sec sec-type="other"><title>Competing interests</title><p>All authors declare that they have no competing interests.</p></sec><glossary><title>Abbreviations</title><def-list><def-item><term id="G1">ATRA</term><def><p>all-<italic>trans</italic> retinoic acid</p></def></def-item><def-item><term id="G2">TEM</term><def><p>transmission electron microscopy</p></def></def-item><def-item><term id="G3">TJs</term><def><p>tight junctions</p></def></def-item><def-item><term id="G4">GO</term><def><p>Gene Ontology</p></def></def-item><def-item><term id="G5">DMSO</term><def><p>dimethyl sulfoxide</p></def></def-item><def-item><term id="G6">EDC</term><def><p>epidermal differentiation complex</p></def></def-item><def-item><term id="G7">SPRRs</term><def><p>small proline-rich region proteins</p></def></def-item><def-item><term id="G8">FLG</term><def><p>filaggrin</p></def></def-item><def-item><term id="G9">LOR</term><def><p>loricrin</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="b1-ijmm-43-04-1789"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahuja</surname><given-names>HS</given-names></name><name><surname>Szanto</surname><given-names>A</given-names></name><name><surname>Nagy</surname><given-names>L</given-names></name><name><surname>Davies</surname><given-names>PJ</given-names></name></person-group><article-title>The retinoid X receptor and its ligands: Versatile regulators of metabolic function, cell differentiation and cell death</article-title><source>J Biol Regul Homeost Agents</source><volume>17</volume><fpage>29</fpage><lpage>45</lpage><year>2003</year><?supplied-pmid 12757020?><pub-id pub-id-type="pmid">12757020</pub-id></element-citation></ref><ref id="b2-ijmm-43-04-1789"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>L</given-names></name><name><surname>Gale</surname><given-names>E</given-names></name><name><surname>Maden</surname><given-names>M</given-names></name></person-group><article-title>The role of retinoic acid in the morphogenesis of the neural tube</article-title><source>J Anat</source><volume>203</volume><fpage>357</fpage><lpage>368</lpage><year>2003</year><pub-id pub-id-type="doi">10.1046/j.1469-7580.2003.00230.x</pub-id><!--<pub-id pub-id-type="pmcid">1571178</pub-id>--><?supplied-pmid 14620376?><pub-id pub-id-type="pmid">14620376</pub-id></element-citation></ref><ref id="b3-ijmm-43-04-1789"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thielitz</surname><given-names>A</given-names></name><name><surname>Gollnick</surname><given-names>H</given-names></name></person-group><article-title>Topical retinoids in acne vulgaris: Update on efficacy and safety</article-title><source>Am J Clin Dermatol</source><volume>9</volume><fpage>369</fpage><lpage>381</lpage><year>2008</year><pub-id pub-id-type="doi">10.2165/0128071-200809060-00003</pub-id><?supplied-pmid 18973403?><pub-id pub-id-type="pmid">18973403</pub-id></element-citation></ref><ref id="b4-ijmm-43-04-1789"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torma</surname><given-names>H</given-names></name><name><surname>Bergstr&#x000f6;m</surname><given-names>A</given-names></name><name><surname>Ghiasifarahani</surname><given-names>G</given-names></name><name><surname>Berne</surname><given-names>B</given-names></name></person-group><article-title>The effect of two endogenous retinoids on the mRNA expression profile in human primary keratinocytes, focusing on genes causing autosomal recessive congenital ichthyosis</article-title><source>Arch Dermatol Res</source><volume>306</volume><fpage>739</fpage><lpage>747</lpage><year>2014</year><pub-id pub-id-type="doi">10.1007/s00403-014-1476-4</pub-id><!--<pub-id pub-id-type="pmcid">4168020</pub-id>--><?supplied-pmid 24925226?><pub-id pub-id-type="pmid">24925226</pub-id></element-citation></ref><ref id="b5-ijmm-43-04-1789"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>ML</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>WQ</given-names></name><name><surname>Ma</surname><given-names>PC</given-names></name><name><surname>Cao</surname><given-names>YP</given-names></name><name><surname>He</surname><given-names>CD</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>LJ</given-names></name></person-group><article-title>All-trans retinoic acid induces cell-cycle arrest in human cutaneous squamous carcinoma cells by inhibiting the mitogen-activated protein kinase-activated protein 1 pathway</article-title><source>Clin Exp Dermatol</source><volume>39</volume><fpage>354</fpage><lpage>360</lpage><year>2014</year><pub-id pub-id-type="doi">10.1111/ced.12227</pub-id><?supplied-pmid 24635079?><pub-id pub-id-type="pmid">24635079</pub-id></element-citation></ref><ref id="b6-ijmm-43-04-1789"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ale</surname><given-names>SI</given-names></name><name><surname>Laugier</surname><given-names>JP</given-names></name><name><surname>Maibach</surname><given-names>HI</given-names></name></person-group><article-title>Differential irritant skin responses to tandem application of topical retinoic acid and sodium lauryl sulphate: Ii. Effect of time between first and second exposure</article-title><source>Br J Dermatol</source><volume>137</volume><fpage>226</fpage><lpage>233</lpage><year>1997</year><pub-id pub-id-type="doi">10.1046/j.1365-2133.1997.18101910.x</pub-id><?supplied-pmid 9292071?><pub-id pub-id-type="pmid">9292071</pub-id></element-citation></ref><ref id="b7-ijmm-43-04-1789"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirschner</surname><given-names>N</given-names></name><name><surname>Houdek</surname><given-names>P</given-names></name><name><surname>Fromm</surname><given-names>M</given-names></name><name><surname>Moll</surname><given-names>I</given-names></name><name><surname>Brandner</surname><given-names>JM</given-names></name></person-group><article-title>Tight junctions form a barrier in human epidermis</article-title><source>Eur J Cell Biol</source><volume>89</volume><fpage>839</fpage><lpage>842</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.ejcb.2010.07.010</pub-id><?supplied-pmid 20732726?><pub-id pub-id-type="pmid">20732726</pub-id></element-citation></ref><ref id="b8-ijmm-43-04-1789"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandner</surname><given-names>JM</given-names></name></person-group><article-title>Importance of tight junctions in relation to skin barrier function</article-title><source>Curr Probl Dermatol</source><volume>49</volume><fpage>27</fpage><lpage>37</lpage><year>2016</year><pub-id pub-id-type="doi">10.1159/000441541</pub-id><?supplied-pmid 26844895?><pub-id pub-id-type="pmid">26844895</pub-id></element-citation></ref><ref id="b9-ijmm-43-04-1789"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuse</surname><given-names>M</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Fujimoto</surname><given-names>K</given-names></name><name><surname>Tsukita</surname><given-names>S</given-names></name></person-group><article-title>A single gene product, claudin-1 or -2, reconstitutes tight junction strands and recruits occludin in fibroblasts</article-title><source>J Cell Biol</source><volume>143</volume><fpage>391</fpage><lpage>401</lpage><year>1998</year><pub-id pub-id-type="doi">10.1083/jcb.143.2.391</pub-id><!--<pub-id pub-id-type="pmcid">2132845</pub-id>--><?supplied-pmid 9786950?><pub-id pub-id-type="pmid">9786950</pub-id></element-citation></ref><ref id="b10-ijmm-43-04-1789"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuse</surname><given-names>M</given-names></name><name><surname>Tsukita</surname><given-names>S</given-names></name></person-group><article-title>Claudins in occluding junctions of humans and flies</article-title><source>Trends Cell Biol</source><volume>16</volume><fpage>181</fpage><lpage>188</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.tcb.2006.02.006</pub-id><?supplied-pmid 16537104?><pub-id pub-id-type="pmid">16537104</pub-id></element-citation></ref><ref id="b11-ijmm-43-04-1789"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turksen</surname><given-names>K</given-names></name><name><surname>Troy</surname><given-names>TC</given-names></name></person-group><article-title>Permeability barrier dysfunction in transgenic mice overexpressing claudin 6</article-title><source>Development</source><volume>129</volume><fpage>1775</fpage><lpage>1784</lpage><year>2002</year><?supplied-pmid 11923212?><pub-id pub-id-type="pmid">11923212</pub-id></element-citation></ref><ref id="b12-ijmm-43-04-1789"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Troy</surname><given-names>TC</given-names></name><name><surname>Rahbar</surname><given-names>R</given-names></name><name><surname>Arabzadeh</surname><given-names>A</given-names></name><name><surname>Cheung</surname><given-names>RM</given-names></name><name><surname>Turksen</surname><given-names>K</given-names></name></person-group><article-title>Delayed epidermal permeability barrier formation and hair follicle aberrations in inv-cldn6 mice</article-title><source>Mech Dev</source><volume>122</volume><fpage>805</fpage><lpage>819</lpage><year>2005</year><pub-id pub-id-type="doi">10.1016/j.mod.2005.03.001</pub-id><?supplied-pmid 15908185?><pub-id pub-id-type="pmid">15908185</pub-id></element-citation></ref><ref id="b13-ijmm-43-04-1789"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugawara</surname><given-names>T</given-names></name><name><surname>Iwamoto</surname><given-names>N</given-names></name><name><surname>Akashi</surname><given-names>M</given-names></name><name><surname>Kojima</surname><given-names>T</given-names></name><name><surname>Hisatsune</surname><given-names>J</given-names></name><name><surname>Sugai</surname><given-names>M</given-names></name><name><surname>Furuse</surname><given-names>M</given-names></name></person-group><article-title>Tight junction dysfunction in the stratum granulosum leads to aberrant stratum corneum barrier function in claudin-1-deficient mice</article-title><source>J Dermatol Sci</source><volume>70</volume><fpage>12</fpage><lpage>18</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.jdermsci.2013.01.002</pub-id><?supplied-pmid 23433550?><pub-id pub-id-type="pmid">23433550</pub-id></element-citation></ref><ref id="b14-ijmm-43-04-1789"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatakeyama</surname><given-names>S</given-names></name><name><surname>Ishida</surname><given-names>K</given-names></name><name><surname>Takeda</surname><given-names>Y</given-names></name></person-group><article-title>Changes in cell characteristics due to retinoic acid; specifically, a decrease in the expression of claudin-1 and increase in claudin-4 within tight junctions in stratified oral keratinocytes</article-title><source>J Periodontal Res</source><volume>45</volume><fpage>207</fpage><lpage>215</lpage><year>2010</year><pub-id pub-id-type="doi">10.1111/j.1600-0765.2009.01219.x</pub-id><pub-id pub-id-type="pmid">19778331</pub-id></element-citation></ref><ref id="b15-ijmm-43-04-1789"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>JM</given-names></name><name><surname>Van Itallie</surname><given-names>CM</given-names></name></person-group><article-title>Physiology and function of the tight junction</article-title><source>Cold Spring Harb Perspect Biol</source><volume>1</volume><fpage>a002584</fpage><year>2009</year><pub-id pub-id-type="doi">10.1101/cshperspect.a002584</pub-id><!--<pub-id pub-id-type="pmcid">2742087</pub-id>--><pub-id pub-id-type="pmid">20066090</pub-id></element-citation></ref><ref id="b16-ijmm-43-04-1789"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuse</surname><given-names>M</given-names></name></person-group><article-title>Knockout animals and natural mutations as experimental and diagnostic tool for studying tight junction functions in vivo</article-title><source>Biochim Biophys Acta</source><volume>1788</volume><fpage>813</fpage><lpage>819</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.bbamem.2008.07.017</pub-id><pub-id pub-id-type="pmid">18706387</pub-id></element-citation></ref><ref id="b17-ijmm-43-04-1789"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuse</surname><given-names>M</given-names></name><name><surname>Hata</surname><given-names>M</given-names></name><name><surname>Furuse</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Haratake</surname><given-names>A</given-names></name><name><surname>Sugitani</surname><given-names>Y</given-names></name><name><surname>Noda</surname><given-names>T</given-names></name><name><surname>Kubo</surname><given-names>A</given-names></name><name><surname>Tsukita</surname><given-names>S</given-names></name></person-group><article-title>Claudin-based tight junctions are crucial for the mammalian epidermal barrier: A lesson from claudin-1-deficient mice</article-title><source>J Cell Biol</source><volume>156</volume><fpage>1099</fpage><lpage>1111</lpage><year>2002</year><pub-id pub-id-type="doi">10.1083/jcb.200110122</pub-id><!--<pub-id pub-id-type="pmcid">2173463</pub-id>--><?supplied-pmid 11889141?><pub-id pub-id-type="pmid">11889141</pub-id></element-citation></ref><ref id="b18-ijmm-43-04-1789"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gruber</surname><given-names>R</given-names></name><name><surname>B&#x000f6;rnchen</surname><given-names>C</given-names></name><name><surname>Rose</surname><given-names>K</given-names></name><name><surname>Daubmann</surname><given-names>A</given-names></name><name><surname>Volksdorf</surname><given-names>T</given-names></name><name><surname>Wladykowski</surname><given-names>E</given-names></name><name><surname>Vidal-Y-Sy</surname><given-names>S</given-names></name><name><surname>Peters</surname><given-names>EM</given-names></name><name><surname>Danso</surname><given-names>M</given-names></name><name><surname>Bouwstra</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Diverse regulation of claudin-1 and claudin-4 in atopic dermatitis</article-title><source>Am J Pathol</source><volume>185</volume><fpage>2777</fpage><lpage>2789</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.ajpath.2015.06.021</pub-id><?supplied-pmid 26319240?><pub-id pub-id-type="pmid">26319240</pub-id></element-citation></ref><ref id="b19-ijmm-43-04-1789"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokumasu</surname><given-names>R</given-names></name><name><surname>Yamaga</surname><given-names>K</given-names></name><name><surname>Yamazaki</surname><given-names>Y</given-names></name><name><surname>Murota</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Tamura</surname><given-names>A</given-names></name><name><surname>Bando</surname><given-names>K</given-names></name><name><surname>Furuta</surname><given-names>Y</given-names></name><name><surname>Katayama</surname><given-names>I</given-names></name><name><surname>Tsukita</surname><given-names>S</given-names></name></person-group><article-title>Dose-dependent role of claudin-1 in vivo in orchestrating features of atopic dermatitis</article-title><source>Proc Natl Acad Sci USA</source><volume>113</volume><fpage>E4061</fpage><lpage>E4068</lpage><year>2016</year><pub-id pub-id-type="doi">10.1073/pnas.1525474113</pub-id><!--<pub-id pub-id-type="pmcid">4948351</pub-id>--><?supplied-pmid 27342862?><pub-id pub-id-type="pmid">27342862</pub-id></element-citation></ref><ref id="b20-ijmm-43-04-1789"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokumasu</surname><given-names>R</given-names></name><name><surname>Tamura</surname><given-names>A</given-names></name><name><surname>Tsukita</surname><given-names>S</given-names></name></person-group><article-title>Time- and dose-dependent claudin contribution to biological functions: Lessons from claudin-1 in skin</article-title><source>Tissue Barriers</source><volume>5</volume><fpage>e1336194</fpage><year>2017</year><pub-id pub-id-type="doi">10.1080/21688370.2017.1336194</pub-id><!--<pub-id pub-id-type="pmcid">5571777</pub-id>--><?supplied-pmid 28650689?><pub-id pub-id-type="pmid">28650689</pub-id></element-citation></ref><ref id="b21-ijmm-43-04-1789"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bo&#x0017c;ek</surname><given-names>A</given-names></name><name><surname>Reich</surname><given-names>A</given-names></name></person-group><article-title>The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment</article-title><source>Adv Clin Exp Med</source><volume>26</volume><fpage>851</fpage><lpage>856</lpage><year>2017</year><pub-id pub-id-type="doi">10.17219/acem/69804</pub-id><pub-id pub-id-type="pmid">29068583</pub-id></element-citation></ref><ref id="b22-ijmm-43-04-1789"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>G</given-names></name><name><surname>Esmann</surname><given-names>J</given-names></name><name><surname>Griffiths</surname><given-names>CE</given-names></name><name><surname>Talwar</surname><given-names>HS</given-names></name><name><surname>Duell</surname><given-names>EA</given-names></name><name><surname>Hammerberg</surname><given-names>C</given-names></name><name><surname>Elder</surname><given-names>JT</given-names></name><name><surname>Finkel</surname><given-names>LJ</given-names></name><name><surname>Karabin</surname><given-names>GD</given-names></name><name><surname>Nickoloff</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Cellular, immunologic and biochemical characterization of topical retinoic acid-treated human skin</article-title><source>J Invest Dermatol</source><volume>96</volume><fpage>699</fpage><lpage>707</lpage><year>1991</year><pub-id pub-id-type="doi">10.1111/1523-1747.ep12470632</pub-id><?supplied-pmid 1673698?><pub-id pub-id-type="pmid">1673698</pub-id></element-citation></ref><ref id="b23-ijmm-43-04-1789"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(&#x02212;Delta Delta C(T)) method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><year>2001</year><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref><ref id="b24-ijmm-43-04-1789"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ovaere</surname><given-names>P</given-names></name><name><surname>Lippens</surname><given-names>S</given-names></name><name><surname>Vandenabeele</surname><given-names>P</given-names></name><name><surname>Declercq</surname><given-names>W</given-names></name></person-group><article-title>The emerging roles of serine protease cascades in the epidermis</article-title><source>Trends Biochem Sci</source><volume>34</volume><fpage>453</fpage><lpage>463</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.tibs.2009.08.001</pub-id><?supplied-pmid 19726197?><pub-id pub-id-type="pmid">19726197</pub-id></element-citation></ref><ref id="b25-ijmm-43-04-1789"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>TJ</given-names></name></person-group><article-title>An update on the safety and efficacy of topical retinoids</article-title><source>Cutis</source><volume>75</volume><fpage>14</fpage><lpage>22</lpage><fpage>24</fpage><comment>discussion 22&#x02013;23</comment><year>2005</year><?supplied-pmid 15773539?><pub-id pub-id-type="pmid">15773539</pub-id></element-citation></ref><ref id="b26-ijmm-43-04-1789"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>JS</given-names></name><name><surname>Shavin</surname><given-names>JS</given-names></name><name><surname>Nighland</surname><given-names>M</given-names></name><name><surname>Grossman</surname><given-names>R</given-names></name></person-group><article-title>Tretinoin microsphere gel 0.1% for photodamaged facial skin: A placebo-controlled trial</article-title><source>Cutis</source><volume>78</volume><fpage>426</fpage><lpage>432</lpage><year>2006</year><pub-id pub-id-type="pmid">17243432</pub-id></element-citation></ref><ref id="b27-ijmm-43-04-1789"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>D</given-names></name><name><surname>Hardman</surname><given-names>MJ</given-names></name><name><surname>Nield</surname><given-names>KM</given-names></name><name><surname>Byrne</surname><given-names>C</given-names></name></person-group><article-title>Differentially expressed late constituents of the epidermal cornified envelope</article-title><source>Proc Natl Acad Sci USA</source><volume>98</volume><fpage>13031</fpage><lpage>13036</lpage><year>2001</year><pub-id pub-id-type="doi">10.1073/pnas.231489198</pub-id><!--<pub-id pub-id-type="pmcid">60819</pub-id>--><?supplied-pmid 11698679?><pub-id pub-id-type="pmid">11698679</pub-id></element-citation></ref><ref id="b28-ijmm-43-04-1789"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer-Hoffert</surname><given-names>U</given-names></name></person-group><article-title>Reddish, scaly, and itchy: How proteases and their inhibitors contribute to inflammatory skin diseases</article-title><source>Arch Immunol Ther Exp (Warsz)</source><volume>57</volume><fpage>345</fpage><lpage>354</lpage><year>2009</year><pub-id pub-id-type="doi">10.1007/s00005-009-0045-6</pub-id><pub-id pub-id-type="pmid">19688185</pub-id></element-citation></ref><ref id="b29-ijmm-43-04-1789"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandilands</surname><given-names>A</given-names></name><name><surname>Sutherland</surname><given-names>C</given-names></name><name><surname>Irvine</surname><given-names>AD</given-names></name><name><surname>McLean</surname><given-names>WH</given-names></name></person-group><article-title>Filaggrin in the frontline: Role in skin barrier function and disease</article-title><source>J Cell Sci</source><volume>122</volume><fpage>1285</fpage><lpage>1294</lpage><year>2009</year><pub-id pub-id-type="doi">10.1242/jcs.033969</pub-id><!--<pub-id pub-id-type="pmcid">2721001</pub-id>--><?supplied-pmid 19386895?><pub-id pub-id-type="pmid">19386895</pub-id></element-citation></ref><ref id="b30-ijmm-43-04-1789"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epp</surname><given-names>N</given-names></name><name><surname>F&#x000fc;rstenberger</surname><given-names>G</given-names></name><name><surname>Muller</surname><given-names>K</given-names></name><name><surname>de Juanes</surname><given-names>S</given-names></name><name><surname>Leitges</surname><given-names>M</given-names></name><name><surname>Hausser</surname><given-names>I</given-names></name><name><surname>Thieme</surname><given-names>F</given-names></name><name><surname>Liebisch</surname><given-names>G</given-names></name><name><surname>Schmitz</surname><given-names>G</given-names></name><name><surname>Krieg</surname><given-names>P</given-names></name></person-group><article-title>12r-lipoxygenase deficiency disrupts epidermal barrier function</article-title><source>J Cell Biol</source><volume>177</volume><fpage>173</fpage><lpage>182</lpage><year>2007</year><pub-id pub-id-type="doi">10.1083/jcb.200612116</pub-id><!--<pub-id pub-id-type="pmcid">2064121</pub-id>--><?supplied-pmid 17403930?><pub-id pub-id-type="pmid">17403930</pub-id></element-citation></ref><ref id="b31-ijmm-43-04-1789"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sybert</surname><given-names>VP</given-names></name><name><surname>Dale</surname><given-names>BA</given-names></name><name><surname>Holbrook</surname><given-names>KA</given-names></name></person-group><article-title>Ichthyosis vulgaris: Identification of a defect in synthesis of filaggrin correlated with an absence of keratohyaline granules</article-title><source>J Invest Dermatol</source><volume>84</volume><fpage>191</fpage><lpage>194</lpage><year>1985</year><pub-id pub-id-type="doi">10.1111/1523-1747.ep12264813</pub-id><?supplied-pmid 2579164?><pub-id pub-id-type="pmid">2579164</pub-id></element-citation></ref><ref id="b32-ijmm-43-04-1789"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponec</surname><given-names>M</given-names></name><name><surname>Boelsma</surname><given-names>E</given-names></name><name><surname>Weerheim</surname><given-names>A</given-names></name><name><surname>Mulder</surname><given-names>A</given-names></name><name><surname>Bouwstra</surname><given-names>J</given-names></name><name><surname>Mommaas</surname><given-names>M</given-names></name></person-group><article-title>Lipid and ultrastructural characterization of reconstructed skin models</article-title><source>Int J Pharm</source><volume>203</volume><fpage>211</fpage><lpage>225</lpage><year>2000</year><pub-id pub-id-type="doi">10.1016/S0378-5173(00)00459-2</pub-id><?supplied-pmid 10967443?><pub-id pub-id-type="pmid">10967443</pub-id></element-citation></ref><ref id="b33-ijmm-43-04-1789"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amen</surname><given-names>N</given-names></name><name><surname>Mathow</surname><given-names>D</given-names></name><name><surname>Rabionet</surname><given-names>M</given-names></name><name><surname>Sandhoff</surname><given-names>R</given-names></name><name><surname>Langbein</surname><given-names>L</given-names></name><name><surname>Gretz</surname><given-names>N</given-names></name><name><surname>J&#x000e4;ckel</surname><given-names>C</given-names></name><name><surname>Grone</surname><given-names>HJ</given-names></name><name><surname>Jennemann</surname><given-names>R</given-names></name></person-group><article-title>Differentiation of epidermal keratinocytes is dependent on glucosylceramide: Ceramide processing</article-title><source>Hum Mol Genet</source><volume>22</volume><fpage>4164</fpage><lpage>4179</lpage><year>2013</year><pub-id pub-id-type="doi">10.1093/hmg/ddt264</pub-id><?supplied-pmid 23748427?><pub-id pub-id-type="pmid">23748427</pub-id></element-citation></ref><ref id="b34-ijmm-43-04-1789"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao-Qiang</surname><given-names>M</given-names></name><name><surname>Jain</surname><given-names>M</given-names></name><name><surname>Feingold</surname><given-names>KR</given-names></name><name><surname>Elias</surname><given-names>PM</given-names></name></person-group><article-title>Secretory phospholipase A2 activity is required for permeability barrier homeostasis</article-title><source>J Invest Dermatol</source><volume>106</volume><fpage>57</fpage><lpage>63</lpage><year>1996</year><pub-id pub-id-type="doi">10.1111/1523-1747.ep12327246</pub-id><?supplied-pmid 8592082?><pub-id pub-id-type="pmid">8592082</pub-id></element-citation></ref><ref id="b35-ijmm-43-04-1789"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Jiang</surname><given-names>YJ</given-names></name><name><surname>Man</surname><given-names>MQ</given-names></name><name><surname>Brown</surname><given-names>B</given-names></name><name><surname>Elias</surname><given-names>PM</given-names></name><name><surname>Feingold</surname><given-names>KR</given-names></name></person-group><article-title>Expression and regulation of 1-acyl-sn-glycerol- 3-phosphate acyltransferases in the epidermis</article-title><source>J Lipid Res</source><volume>46</volume><fpage>2448</fpage><lpage>2457</lpage><year>2005</year><pub-id pub-id-type="doi">10.1194/jlr.M500258-JLR200</pub-id><?supplied-pmid 16150824?><pub-id pub-id-type="pmid">16150824</pub-id></element-citation></ref><ref id="b36-ijmm-43-04-1789"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krieg</surname><given-names>P</given-names></name><name><surname>F&#x000fc;rstenberger</surname><given-names>G</given-names></name></person-group><article-title>The role of lipoxygenases in epidermis</article-title><source>Biochim Biophys Acta</source><year>1841</year><fpage>390</fpage><lpage>400</lpage><year>2014</year></element-citation></ref><ref id="b37-ijmm-43-04-1789"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feingold</surname><given-names>KR</given-names></name></person-group><article-title>Thematic review series: Skin lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasis</article-title><source>J Lipid Res</source><volume>48</volume><fpage>2531</fpage><lpage>2546</lpage><year>2007</year><pub-id pub-id-type="doi">10.1194/jlr.R700013-JLR200</pub-id><?supplied-pmid 17872588?><pub-id pub-id-type="pmid">17872588</pub-id></element-citation></ref><ref id="b38-ijmm-43-04-1789"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuki</surname><given-names>T</given-names></name><name><surname>Haratake</surname><given-names>A</given-names></name><name><surname>Koishikawa</surname><given-names>H</given-names></name><name><surname>Morita</surname><given-names>K</given-names></name><name><surname>Miyachi</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>S</given-names></name></person-group><article-title>Tight junction proteins in keratinocytes: Localization and contribution to barrier function</article-title><source>Exp Dermatol</source><volume>16</volume><fpage>324</fpage><lpage>330</lpage><year>2007</year><pub-id pub-id-type="doi">10.1111/j.1600-0625.2006.00539.x</pub-id><?supplied-pmid 17359339?><pub-id pub-id-type="pmid">17359339</pub-id></element-citation></ref><ref id="b39-ijmm-43-04-1789"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Saeki</surname><given-names>Y</given-names></name><name><surname>Kurasawa</surname><given-names>M</given-names></name><name><surname>Kuroda</surname><given-names>S</given-names></name><name><surname>Arase</surname><given-names>S</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name></person-group><article-title>Effect of RNA interference of tight junction-related molecules on intercellular barrier function in cultured human keratinocytes</article-title><source>Arch Dermatol Res</source><volume>300</volume><fpage>517</fpage><lpage>524</lpage><year>2008</year><pub-id pub-id-type="doi">10.1007/s00403-008-0868-8</pub-id><?supplied-pmid 18560860?><pub-id pub-id-type="pmid">18560860</pub-id></element-citation></ref><ref id="b40-ijmm-43-04-1789"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Benedetto</surname><given-names>A</given-names></name><name><surname>Rafaels</surname><given-names>NM</given-names></name><name><surname>McGirt</surname><given-names>LY</given-names></name><name><surname>Ivanov</surname><given-names>AI</given-names></name><name><surname>Georas</surname><given-names>SN</given-names></name><name><surname>Cheadle</surname><given-names>C</given-names></name><name><surname>Berger</surname><given-names>AE</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Vidyasagar</surname><given-names>S</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><etal/></person-group><article-title>Tight junction defects in patients with atopic dermatitis</article-title><source>J Allergy Clin Immunol</source><volume>127</volume><fpage>773</fpage><lpage>786</lpage><fpage>e1</fpage><lpage>7</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.jaci.2010.10.018</pub-id><pub-id pub-id-type="pmid">21163515</pub-id></element-citation></ref><ref id="b41-ijmm-43-04-1789"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirschner</surname><given-names>N</given-names></name><name><surname>Rosenthal</surname><given-names>R</given-names></name><name><surname>Furuse</surname><given-names>M</given-names></name><name><surname>Moll</surname><given-names>I</given-names></name><name><surname>Fromm</surname><given-names>M</given-names></name><name><surname>Brandner</surname><given-names>JM</given-names></name></person-group><article-title>Contribution of tight junction proteins to ion, macromolecule, and water barrier in keratinocytes</article-title><source>J Invest Dermatol</source><volume>133</volume><fpage>1161</fpage><lpage>1169</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/jid.2012.507</pub-id><?supplied-pmid 23407391?><pub-id pub-id-type="pmid">23407391</pub-id></element-citation></ref><ref id="b42-ijmm-43-04-1789"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubo</surname><given-names>T</given-names></name><name><surname>Sugimoto</surname><given-names>K</given-names></name><name><surname>Kojima</surname><given-names>T</given-names></name><name><surname>Sawada</surname><given-names>N</given-names></name><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Ichimiya</surname><given-names>S</given-names></name></person-group><article-title>Tight junction protein claudin-4 is modulated via &#x00394;np63 in human keratinocytes</article-title><source>Biochem Biophys Res Commun</source><volume>455</volume><fpage>205</fpage><lpage>211</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2014.10.148</pub-id><?supplied-pmid 25449274?><pub-id pub-id-type="pmid">25449274</pub-id></element-citation></ref><ref id="b43-ijmm-43-04-1789"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Telgenhoff</surname><given-names>D</given-names></name><name><surname>Ramsay</surname><given-names>S</given-names></name><name><surname>Hilz</surname><given-names>S</given-names></name><name><surname>Slusarewicz</surname><given-names>P</given-names></name><name><surname>Shroot</surname><given-names>B</given-names></name></person-group><article-title>Claudin 2 mRNA and protein are present in human keratinocytes and may be regulated by all-trans-retinoic acid</article-title><source>Skin Pharmacol Physiol</source><volume>21</volume><fpage>211</fpage><lpage>217</lpage><year>2008</year><pub-id pub-id-type="doi">10.1159/000135637</pub-id><?supplied-pmid 18509255?><pub-id pub-id-type="pmid">18509255</pub-id></element-citation></ref><ref id="b44-ijmm-43-04-1789"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muto</surname><given-names>S</given-names></name><name><surname>Hata</surname><given-names>M</given-names></name><name><surname>Taniguchi</surname><given-names>J</given-names></name><name><surname>Tsuruoka</surname><given-names>S</given-names></name><name><surname>Moriwaki</surname><given-names>K</given-names></name><name><surname>Saitou</surname><given-names>M</given-names></name><name><surname>Furuse</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Fujimura</surname><given-names>A</given-names></name><name><surname>Imai</surname><given-names>M</given-names></name><etal/></person-group><article-title>Claudin-2-deficient mice are defective in the leaky and cation-selective paracellular permeability properties of renal proximal tubules</article-title><source>Proc Natl Acad Sci USA</source><volume>107</volume><fpage>8011</fpage><lpage>8016</lpage><year>2010</year><pub-id pub-id-type="doi">10.1073/pnas.0912901107</pub-id><!--<pub-id pub-id-type="pmcid">2867900</pub-id>--><?supplied-pmid 20385797?><pub-id pub-id-type="pmid">20385797</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-ijmm-43-04-1789" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Effect of ATRA on morphological changes and PASI score on the back skin of mice. (A) After 5 days of treatment, no obvious alterations were detected in the control skin. Circumscribed erythema occurred after 3 days of ATRA application and gradually expanded, presenting as fine flat scales covering the surface of the erythema and peaking at 5 days. (B) The PASI scoring system was used to assess the severity of inflammation on the back skin of the mice. <sup>*</sup>P&#x0003c;0.05, <sup>**</sup>P&#x0003c;0.01 vs. respective control. PASI, Psoriasis Area and Severity Index; ATRA, all-<italic>trans</italic> retinoic acid.</p></caption><graphic xlink:href="IJMM-43-04-1789-g00"/></fig><fig id="f2-ijmm-43-04-1789" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Effect of ATRA on histological changes in the mouse epidermis and quantitative analysis. (A) The mice were treated with topical 0.1% ATRA cream or oil/water cream (vehicle) twice a day. The mice were sacrificed after 5 days of ATRA treatment. The stratum corneum was impaired and the number of epidermal cell layers and epidermal thickness were increased in ATRA-treated mice. Parakeratosis (black arrows), intercellular edema (triangles), and dermal inflammatory cell infiltration (white arrows) were also observed. n=6 per group. Scale bar, 100 <italic>&#x000b5;</italic>m. A representative image was selected from each group. (B) Quantitative analysis of epidermal cell layers, epidermal thickness, parakeratosis spongiosis, perivascular lymphocytic infiltration and telangiectasia. ATRA, all-<italic>trans</italic> retinoic acid.</p></caption><graphic xlink:href="IJMM-43-04-1789-g01"/></fig><fig id="f3-ijmm-43-04-1789" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Effect of ATRA on ultrastructural alterations in the mouse epidermis. (A) The stratum corneum was impaired and the number of epidermal cell layers and epidermal thickness were increased. The number of KGs around granular cells were decreased (arrows). (B) There were multiple lipid droplets in the corneocytes (arrows). The volume of the spinous layer cells was increased, the nucleoli were significantly larger, and the intercellular space was widened (triangles). (C) Desmosomes were reduced in number and damaged (arrows). n=3/group. A representative image is presented for each group. (D) The numbers of KGs, lipid droplets and desmosomes were quantified. KC, keratinocyte; SC, stratum corneum; SG, stratum granulosum; D, desmosome; N, nucleus; KGs, keratinocyte granules; ATRA, all-<italic>trans</italic> retinoic acid.</p></caption><graphic xlink:href="IJMM-43-04-1789-g02"/></fig><fig id="f4-ijmm-43-04-1789" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Top ten pathways of up- and downregulated genes. The bar plots indicate the top ten (A) down- and (B) upregulated enrichment score [&#x02212;log <sup>(P-value)</sup> 10] values of the significantly enriched pathways (n=1 per group). The top ten (C) down- and (D) upregulated-fold enrichment [(Count/Pop.Hits)/(List.Total/Pop.Total)] values of the significant biological processes are presented. The bar plots indicated the top ten (E) down- and (F) upregulated-fold enrichment [(Count/Pop.Hits)/(List.Total/Pop.Total)] values of the significant cellular components. The top ten (G) down- and (H) upregulated-fold enrichment [(Count/Pop.Hits)/(List.Total/Pop.Total)] values of the significant molecular functions are presented. Count, the number of differentially expressed genes associated with the listed GOID; Pop.Hits, the number of background population genes associated with the listed GOID; List.Total, the total number of differentially expressed genes; and Pop.Total, the total number of background population genes. GO, Gene Ontology.</p></caption><graphic xlink:href="IJMM-43-04-1789-g03"/></fig><fig id="f5-ijmm-43-04-1789" orientation="portrait" position="float"><label>Figure 5</label><caption><p>mRNA and protein expression levels of CLDN1 and CLDN4 in immortalized keratinocyte HaCaT cells treated with ATRA. HaCaT cells were incubated with or without 1 <italic>&#x000b5;</italic>M ATRA for 36 h. (A) In the cells, CLDN-4, TJP3 and JGB4 were upregulated, while CLDN1 was downregulated. (B) In mice, CLDN1 and FLG were downregulated, while CLDN4 and CLDN2 were upregulated. (C) CLDN1 and CLDN4 protein expression levels were determined by western blotting. &#x003b2;-actin was used as a loading control. Data are presented as the mean &#x000b1; standard deviation from three independent experiments performed in triplicate (n=3). <sup>*</sup>P&#x0003c;0.05 vs. respective vehicle group. CLDN, Claudin; ATRA, all-<italic>trans</italic> retinoic acid; TJP3, tight junction protein 3; GJB4, gap junction protein &#x003b2;4; FLG, filaggrin.</p></caption><graphic xlink:href="IJMM-43-04-1789-g04"/></fig><fig id="f6-ijmm-43-04-1789" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Localization and expression of CLDN1 and CLDN4 in cultured HaCaT cells treated with ATRA. The localization of CLDN4 and CLDN1 (both red) was observed at the intercellular border in a string-like pattern in HaCaT cells treated with the vehicle. In ATRA-treated cells, CLDN4 immunofluorescence at the cell-cell contact sites appeared to be more intense compared with that in the vehicle group, while CLDN1 exhibited increased punctate localization in ATRA-treated cells. DAPI was used as a counterstain (blue). Scale bar, 20 <italic>&#x000b5;</italic>m. CLDN, Claudin; ATRA, all-<italic>trans</italic> retinoic acid.</p></caption><graphic xlink:href="IJMM-43-04-1789-g05"/></fig><fig id="f7-ijmm-43-04-1789" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Effect of ATRA on the localization and expression of CLDN1 and CLDN4 in mouse epidermal tissues. Following ATRA treatment, CLDN1 (red) was expressed at the cell-cell borders in the granular and spinous layers, but disappeared from the basal layers. CLDN4 (red) was expressed at the cell-cell borders in the granular layer and was enhanced in the upper spinous layer and granular layer following treatment with ATRA. DAPI was used as a counterstain (blue). Dotted lines indicate the basal layer. Scale bar, 20 <italic>&#x000b5;</italic>m. n=3 per group. A representative image was selected from each group. CLDN, Claudin; ATRA, all-<italic>trans</italic> retinoic acid.</p></caption><graphic xlink:href="IJMM-43-04-1789-g06"/></fig><table-wrap id="tI-ijmm-43-04-1789" orientation="portrait" position="float"><label>Table I</label><caption><p>Primers for reverse transcription-quantitative polymerase chain reaction.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Gene symbol</th><th valign="top" align="left" rowspan="1" colspan="1">Primers</th></tr></thead><tbody><tr><td rowspan="2" valign="top" align="left" colspan="1">&#x003b2;-actin</td><td valign="top" align="left" rowspan="1" colspan="1">F-5&#x02032;-AGCAGAGAATGGAAGAGTAAA-3&#x02032;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">R-5&#x02032;-ATGCTGCTTACATGTCTCGAT-3&#x02032;</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">CLDN4</td><td valign="top" align="left" rowspan="1" colspan="1">F-5&#x02032;-TATGGATGAACTGCGTGGTG-3&#x02032;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">R-5&#x02032;-GATGATGVTGATGATGACGAG-3&#x02032;</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">CLDN1</td><td valign="top" align="left" rowspan="1" colspan="1">F-5&#x02032;-GAAGTGTATGAAGTGCTTGG-3&#x02032;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">R-5&#x02032;-GGGTCATAGGGTCATAGAAT-3&#x02032;</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">CLDN2</td><td valign="top" align="left" rowspan="1" colspan="1">F-5&#x02032;-GTGAAGGCAGAGATGAGAAGAGG-3&#x02032;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">R-5&#x02032;-ATGGGATTTGGGCTTTTGG-3&#x02032;</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">FLG</td><td valign="top" align="left" rowspan="1" colspan="1">F-5&#x02032;-AGACTGGGAGGCAAGCTACAAC-3&#x02032;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">R-5&#x02032;-TGGTTTGGAGTGGGATTGCT-3&#x02032;</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ijmm-43-04-1789"><p>F, forward; R, reverse; CLDN, Claudin; FLG, filaggrin.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tII-ijmm-43-04-1789" orientation="portrait" position="float"><label>Table II</label><caption><p>Downregulation of epidermal barrier-associated genes following treatment with all-<italic>trans</italic> retinoic acid in mouse skin (n=1 per group;-fold change &#x0003e;2; P&#x0003c;0.05).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4" valign="top" align="left" rowspan="1">A, Cornified envelope components
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">GenBank accession no.</th><th valign="top" align="left" rowspan="1" colspan="1">Gene name</th><th valign="top" align="left" rowspan="1" colspan="1">Gene full name</th><th valign="top" align="right" rowspan="1" colspan="1">Fold downregulation</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">AF510860</td><td valign="top" align="left" rowspan="1" colspan="1">FLG</td><td valign="top" align="left" rowspan="1" colspan="1">Filagrin</td><td valign="top" align="right" rowspan="1" colspan="1">2.13</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC108980</td><td valign="top" align="left" rowspan="1" colspan="1">FOXN1</td><td valign="top" align="left" rowspan="1" colspan="1">Forkhead box N1</td><td valign="top" align="right" rowspan="1" colspan="1">2.42</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC107019</td><td valign="top" align="left" rowspan="1" colspan="1">SPRR4</td><td valign="top" align="left" rowspan="1" colspan="1">Small proline-rich protein 4</td><td valign="top" align="right" rowspan="1" colspan="1">2.67</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC109181</td><td valign="top" align="left" rowspan="1" colspan="1">LCE1M</td><td valign="top" align="left" rowspan="1" colspan="1">Late cornified envelope 1M</td><td valign="top" align="right" rowspan="1" colspan="1">6.64</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC031486</td><td valign="top" align="left" rowspan="1" colspan="1">PPHLN1</td><td valign="top" align="left" rowspan="1" colspan="1">Periphilin 1</td><td valign="top" align="right" rowspan="1" colspan="1">2.40</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC119192</td><td valign="top" align="left" rowspan="1" colspan="1">GPRC5D</td><td valign="top" align="left" rowspan="1" colspan="1">Protein-coupled receptor, class C, group 5, member D</td><td valign="top" align="right" rowspan="1" colspan="1">20.66</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1"><bold>B, Intermediate filament</bold></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GenBank accession no.</td><td valign="top" align="left" rowspan="1" colspan="1">Gene name</td><td valign="top" align="left" rowspan="1" colspan="1">Gene full name</td><td valign="top" align="right" rowspan="1" colspan="1">Fold downregulation</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC003472</td><td valign="top" align="left" rowspan="1" colspan="1">KRT23</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 23</td><td valign="top" align="right" rowspan="1" colspan="1">2.67</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC129847</td><td valign="top" align="left" rowspan="1" colspan="1">KRT24</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 24</td><td valign="top" align="right" rowspan="1" colspan="1">2.66</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC018391</td><td valign="top" align="left" rowspan="1" colspan="1">KRT25</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 25</td><td valign="top" align="right" rowspan="1" colspan="1">6.56</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC116672</td><td valign="top" align="left" rowspan="1" colspan="1">KRT26</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 26</td><td valign="top" align="right" rowspan="1" colspan="1">7.78</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AB288231</td><td valign="top" align="left" rowspan="1" colspan="1">KRT28</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 28</td><td valign="top" align="right" rowspan="1" colspan="1">4.28</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC117553</td><td valign="top" align="left" rowspan="1" colspan="1">KRT32</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 32</td><td valign="top" align="right" rowspan="1" colspan="1">6.04</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC12542</td><td valign="top" align="left" rowspan="1" colspan="1">KRT34</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 34</td><td valign="top" align="right" rowspan="1" colspan="1">101.08</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC100542</td><td valign="top" align="left" rowspan="1" colspan="1">KRT35</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 35</td><td valign="top" align="right" rowspan="1" colspan="1">6.86</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC119521</td><td valign="top" align="left" rowspan="1" colspan="1">KRT40</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 40</td><td valign="top" align="right" rowspan="1" colspan="1">10.11</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC125346</td><td valign="top" align="left" rowspan="1" colspan="1">KRT71</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 71</td><td valign="top" align="right" rowspan="1" colspan="1">2.90</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC067067</td><td valign="top" align="left" rowspan="1" colspan="1">KRT73</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 73</td><td valign="top" align="right" rowspan="1" colspan="1">4.34</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC107395</td><td valign="top" align="left" rowspan="1" colspan="1">KRT77</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 77</td><td valign="top" align="right" rowspan="1" colspan="1">9.12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC119366</td><td valign="top" align="left" rowspan="1" colspan="1">KRT80</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 80</td><td valign="top" align="right" rowspan="1" colspan="1">2.21</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AF312018</td><td valign="top" align="left" rowspan="1" colspan="1">KRT81</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 81</td><td valign="top" align="right" rowspan="1" colspan="1">30.65</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC10897</td><td valign="top" align="left" rowspan="1" colspan="1">KRT82</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 82</td><td valign="top" align="right" rowspan="1" colspan="1">10.18</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC152922</td><td valign="top" align="left" rowspan="1" colspan="1">KRT85</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 85</td><td valign="top" align="right" rowspan="1" colspan="1">19.46</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> BC029257</td><td valign="top" align="left" rowspan="1" colspan="1">KRT33A</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 33A</td><td valign="top" align="right" rowspan="1" colspan="1">39.26</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_013570</td><td valign="top" align="left" rowspan="1" colspan="1">KRT33B</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 33B</td><td valign="top" align="right" rowspan="1" colspan="1">4.79</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_001085526</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP1-2</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 1-3</td><td valign="top" align="right" rowspan="1" colspan="1">13.42</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">XM_894811</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP3-1</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 3-1</td><td valign="top" align="right" rowspan="1" colspan="1">29.03</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC156698</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP4-2</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 4-2</td><td valign="top" align="right" rowspan="1" colspan="1">19.09</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_026834</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP4-6</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 4-6</td><td valign="top" align="right" rowspan="1" colspan="1">24.72</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC115508</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP4-7</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 4-7</td><td valign="top" align="right" rowspan="1" colspan="1">33.02</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_001085547</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP4-8</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 4-8</td><td valign="top" align="right" rowspan="1" colspan="1">43.14</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_001085548</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP4-9</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 4-9</td><td valign="top" align="right" rowspan="1" colspan="1">24.62</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC016249</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP4-16</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 4-16</td><td valign="top" align="right" rowspan="1" colspan="1">42.20</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_015809</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP5-4</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 5-4</td><td valign="top" align="right" rowspan="1" colspan="1">19.54</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_027771</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP7-1</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 7-1</td><td valign="top" align="right" rowspan="1" colspan="1">137.50</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AK133727</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP8-1</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 8-1</td><td valign="top" align="right" rowspan="1" colspan="1">18.92</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC116210</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP9-1</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 9-1</td><td valign="top" align="right" rowspan="1" colspan="1">11.56</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC156686</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP9-3</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 9-3</td><td valign="top" align="right" rowspan="1" colspan="1">35.46</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_001085527</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP9-5</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 9-5</td><td valign="top" align="right" rowspan="1" colspan="1">12.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC116219</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP15</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 15</td><td valign="top" align="right" rowspan="1" colspan="1">60.31</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC116200</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP19-4</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 19-4</td><td valign="top" align="right" rowspan="1" colspan="1">10.75</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC115545</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP19-3</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 19-3</td><td valign="top" align="right" rowspan="1" colspan="1">8.54</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC132612</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP6-5</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 6-5</td><td valign="top" align="right" rowspan="1" colspan="1">14.96</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC132658</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP16-3</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 16-3</td><td valign="top" align="right" rowspan="1" colspan="1">39.91</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC128283</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP26-1</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 26-1</td><td valign="top" align="right" rowspan="1" colspan="1">6.51</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1"><bold>C, Lipid metabolic process</bold></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GenBank accession no.</td><td valign="top" align="left" rowspan="1" colspan="1">Gene name</td><td valign="top" align="left" rowspan="1" colspan="1">Gene full name</td><td valign="top" align="right" rowspan="1" colspan="1">Fold downregulation</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AK003689</td><td valign="top" align="left" rowspan="1" colspan="1">LYPLA2</td><td valign="top" align="left" rowspan="1" colspan="1">Lysophospholipase II</td><td valign="top" align="right" rowspan="1" colspan="1">2.00</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC027524</td><td valign="top" align="left" rowspan="1" colspan="1">PLA2G2E</td><td valign="top" align="left" rowspan="1" colspan="1">Phospholipase A2, group IIE</td><td valign="top" align="right" rowspan="1" colspan="1">2.60</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC148434</td><td valign="top" align="left" rowspan="1" colspan="1">PLCH2</td><td valign="top" align="left" rowspan="1" colspan="1">Phospholipase C eta 2</td><td valign="top" align="right" rowspan="1" colspan="1">2.13</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC047281</td><td valign="top" align="left" rowspan="1" colspan="1">AGPAT4</td><td valign="top" align="left" rowspan="1" colspan="1">1-acylglycerol-3-phosphate O-acyltransferase 4</td><td valign="top" align="right" rowspan="1" colspan="1">3.81</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC031987</td><td valign="top" align="left" rowspan="1" colspan="1">AGPAT5</td><td valign="top" align="left" rowspan="1" colspan="1">1-acylglycerol-3-phosphate O-acyltransferase 5</td><td valign="top" align="right" rowspan="1" colspan="1">3.17</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AK019476</td><td valign="top" align="left" rowspan="1" colspan="1">SMPD3</td><td valign="top" align="left" rowspan="1" colspan="1">Sphingomyelin Phosphodiesterase 3 neutral</td><td valign="top" align="right" rowspan="1" colspan="1">2.15</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AK088962</td><td valign="top" align="left" rowspan="1" colspan="1">SMPD2</td><td valign="top" align="left" rowspan="1" colspan="1">Sphingomyelin phosphodiesterase 2 neutral</td><td valign="top" align="right" rowspan="1" colspan="1">2.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC013751</td><td valign="top" align="left" rowspan="1" colspan="1">ALOX12E</td><td valign="top" align="left" rowspan="1" colspan="1">Arachidonate lipoxygenase</td><td valign="top" align="right" rowspan="1" colspan="1">3.90</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC043059</td><td valign="top" align="left" rowspan="1" colspan="1">LASS5/Cers5</td><td valign="top" align="left" rowspan="1" colspan="1">Epidermal ceramide synthase 5</td><td valign="top" align="right" rowspan="1" colspan="1">2.82</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC075627</td><td valign="top" align="left" rowspan="1" colspan="1">DGKK</td><td valign="top" align="left" rowspan="1" colspan="1">Diacylglycerol kinase &#x003ba;</td><td valign="top" align="right" rowspan="1" colspan="1">3.89</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC021597</td><td valign="top" align="left" rowspan="1" colspan="1">APOM</td><td valign="top" align="left" rowspan="1" colspan="1">Apolipoprotein M</td><td valign="top" align="right" rowspan="1" colspan="1">2.58</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC006863</td><td valign="top" align="left" rowspan="1" colspan="1">FAAH</td><td valign="top" align="left" rowspan="1" colspan="1">Fatty acid amide hydrolase</td><td valign="top" align="right" rowspan="1" colspan="1">2.22</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC071266</td><td valign="top" align="left" rowspan="1" colspan="1">FADS3</td><td valign="top" align="left" rowspan="1" colspan="1">Fatty acid desaturase 3</td><td valign="top" align="right" rowspan="1" colspan="1">2.53</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1"><bold>D, Gap junction</bold></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GenBank accession no.</td><td valign="top" align="left" rowspan="1" colspan="1">Gene name</td><td valign="top" align="left" rowspan="1" colspan="1">Gene full name</td><td valign="top" align="right" rowspan="1" colspan="1">Fold downregulation</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AY427554</td><td valign="top" align="left" rowspan="1" colspan="1">GJA1</td><td valign="top" align="left" rowspan="1" colspan="1">Gap junction protein &#x003b1;1</td><td valign="top" align="right" rowspan="1" colspan="1">2.00</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AY390399</td><td valign="top" align="left" rowspan="1" colspan="1">GJA3</td><td valign="top" align="left" rowspan="1" colspan="1">Gap junction protein &#x003b1;3</td><td valign="top" align="right" rowspan="1" colspan="1">2.57</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC024387</td><td valign="top" align="left" rowspan="1" colspan="1">GJB3</td><td valign="top" align="left" rowspan="1" colspan="1">Gap junction protein &#x003b2;3</td><td valign="top" align="right" rowspan="1" colspan="1">2.77</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1"><bold>E, Tight junction</bold></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GenBank accession no.</td><td valign="top" align="left" rowspan="1" colspan="1">Gene name</td><td valign="top" align="left" rowspan="1" colspan="1">Gene full name</td><td valign="top" align="right" rowspan="1" colspan="1">Fold downregulation</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AK165750</td><td valign="top" align="left" rowspan="1" colspan="1">PRKCZ</td><td valign="top" align="left" rowspan="1" colspan="1">Protein kinase C &#x003b6;</td><td valign="top" align="right" rowspan="1" colspan="1">2.37</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DQ682659</td><td valign="top" align="left" rowspan="1" colspan="1">MARVELD2</td><td valign="top" align="left" rowspan="1" colspan="1">MARVEL domain containing 2</td><td valign="top" align="right" rowspan="1" colspan="1">3.81</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AK190015</td><td valign="top" align="left" rowspan="1" colspan="1">TJAP1</td><td valign="top" align="left" rowspan="1" colspan="1">Tight junction associated protein 1</td><td valign="top" align="right" rowspan="1" colspan="1">2.08</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC049662</td><td valign="top" align="left" rowspan="1" colspan="1">MPP7</td><td valign="top" align="left" rowspan="1" colspan="1">Membrane palmitoylated protein 7</td><td valign="top" align="right" rowspan="1" colspan="1">2.11</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1"><bold>F, Desmosome</bold></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GenBank accession no.</td><td valign="top" align="left" rowspan="1" colspan="1">Gene name</td><td valign="top" align="left" rowspan="1" colspan="1">Gene full name</td><td valign="top" align="right" rowspan="1" colspan="1">Fold downregulation</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC020144</td><td valign="top" align="left" rowspan="1" colspan="1">DSG2</td><td valign="top" align="left" rowspan="1" colspan="1">Desmoglein 2</td><td valign="top" align="right" rowspan="1" colspan="1">4.48</td></tr></tbody></table></table-wrap><table-wrap id="tIII-ijmm-43-04-1789" orientation="portrait" position="float"><label>Table III</label><caption><p>Upregulation of epidermal barrier-associated genes following treatment with all-<italic>trans</italic> retinoic acid in the mouse skin (n=1 per group;-fold change &#x0003e;2; P&#x0003c;0.05).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4" valign="top" align="left" rowspan="1">A, Cornified envelope components
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">GenBank accession no.</th><th valign="top" align="left" rowspan="1" colspan="1">Gene name</th><th valign="top" align="left" rowspan="1" colspan="1">Gene full name</th><th valign="top" align="left" rowspan="1" colspan="1">Fold upregulation</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">BC115788</td><td valign="top" align="left" rowspan="1" colspan="1">LCE3B</td><td valign="top" align="left" rowspan="1" colspan="1">Late cornified envelope 3B</td><td valign="top" align="left" rowspan="1" colspan="1">3.17</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC119239</td><td valign="top" align="left" rowspan="1" colspan="1">LCE3C</td><td valign="top" align="left" rowspan="1" colspan="1">Late cornified envelope 3C</td><td valign="top" align="left" rowspan="1" colspan="1">5.35</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC125542</td><td valign="top" align="left" rowspan="1" colspan="1">SPRR2J</td><td valign="top" align="left" rowspan="1" colspan="1">Small proline-rich protein 2J</td><td valign="top" align="left" rowspan="1" colspan="1">2.38</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC130233</td><td valign="top" align="left" rowspan="1" colspan="1">SPRR2G</td><td valign="top" align="left" rowspan="1" colspan="1">Small proline-rich protein 2G</td><td valign="top" align="left" rowspan="1" colspan="1">3.57</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC078629</td><td valign="top" align="left" rowspan="1" colspan="1">S100A8</td><td valign="top" align="left" rowspan="1" colspan="1">S100 calcium binding protein A8 (calgranulin A)</td><td valign="top" align="left" rowspan="1" colspan="1">3.31</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AK143826</td><td valign="top" align="left" rowspan="1" colspan="1">S100A9</td><td valign="top" align="left" rowspan="1" colspan="1">S100 calcium binding protein A9 (calgranulin B)</td><td valign="top" align="left" rowspan="1" colspan="1">3.81</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1"><bold>B, Serine protease and protease inhibitors</bold></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GenBank accession no.</td><td valign="top" align="left" rowspan="1" colspan="1">Gene name</td><td valign="top" align="left" rowspan="1" colspan="1">Gene full name</td><td valign="top" align="left" rowspan="1" colspan="1">Fold upregulation</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC031119</td><td valign="top" align="left" rowspan="1" colspan="1">KLK6</td><td valign="top" align="left" rowspan="1" colspan="1">Kallikrein related-peptidase 6</td><td valign="top" align="left" rowspan="1" colspan="1">3.22</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC002100</td><td valign="top" align="left" rowspan="1" colspan="1">KLK10</td><td valign="top" align="left" rowspan="1" colspan="1">Kallikrein related-peptidase 10</td><td valign="top" align="left" rowspan="1" colspan="1">2.90</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">XM_893506</td><td valign="top" align="left" rowspan="1" colspan="1">KLK12</td><td valign="top" align="left" rowspan="1" colspan="1">Kallikrein related-peptidase 12</td><td valign="top" align="left" rowspan="1" colspan="1">2.50</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC054091</td><td valign="top" align="left" rowspan="1" colspan="1">SERPINE1</td><td valign="top" align="left" rowspan="1" colspan="1">Serine (cysteine) proteinase inhibitor, clade E, member 1</td><td valign="top" align="left" rowspan="1" colspan="1">2.15</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC010675</td><td valign="top" align="left" rowspan="1" colspan="1">SERPINE2</td><td valign="top" align="left" rowspan="1" colspan="1">Serine (cysteine) proteinase inhibitor, clade E, member 2</td><td valign="top" align="left" rowspan="1" colspan="1">2.98</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1"><bold>C, Lipid metabolic process</bold></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GenBank accession no.</td><td valign="top" align="left" rowspan="1" colspan="1">Gene name</td><td valign="top" align="left" rowspan="1" colspan="1">Gene full name</td><td valign="top" align="left" rowspan="1" colspan="1">Fold upregulation</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC010829</td><td valign="top" align="left" rowspan="1" colspan="1">ACNAT2</td><td valign="top" align="left" rowspan="1" colspan="1">Acyl-coenzyme A amino acid N-acyltransferase 2</td><td valign="top" align="left" rowspan="1" colspan="1">2.03</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DQ469311</td><td valign="top" align="left" rowspan="1" colspan="1">ACNAT1</td><td valign="top" align="left" rowspan="1" colspan="1">Acyl-coenzyme A amino acid N-acyltransferase 1</td><td valign="top" align="left" rowspan="1" colspan="1">2.94</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AK171255</td><td valign="top" align="left" rowspan="1" colspan="1">ACOT11</td><td valign="top" align="left" rowspan="1" colspan="1">Acyl-CoA thioesterase 11</td><td valign="top" align="left" rowspan="1" colspan="1">3.73</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC050828</td><td valign="top" align="left" rowspan="1" colspan="1">UGCG</td><td valign="top" align="left" rowspan="1" colspan="1">UDP-glucose ceramide glucosyltransferase</td><td valign="top" align="left" rowspan="1" colspan="1">2.21</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> BC060600</td><td valign="top" align="left" rowspan="1" colspan="1">PLA2G4E</td><td valign="top" align="left" rowspan="1" colspan="1">Phospholipase A2, group IVE</td><td valign="top" align="left" rowspan="1" colspan="1">2.39</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC003470</td><td valign="top" align="left" rowspan="1" colspan="1">PLA1A</td><td valign="top" align="left" rowspan="1" colspan="1">Phospholipase A1 member A</td><td valign="top" align="left" rowspan="1" colspan="1">2.06</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC003943</td><td valign="top" align="left" rowspan="1" colspan="1">DPAGT1</td><td valign="top" align="left" rowspan="1" colspan="1">Dolichyl-phosphate (UDP-N-acetylglucosamine) glycerol</td><td valign="top" align="left" rowspan="1" colspan="1">2.10</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1"><bold>D, Tight junction</bold></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GenBank accession no.</td><td valign="top" align="left" rowspan="1" colspan="1">Gene name</td><td valign="top" align="left" rowspan="1" colspan="1">Gene full name</td><td valign="top" align="left" rowspan="1" colspan="1">Fold upregulation</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC015252</td><td valign="top" align="left" rowspan="1" colspan="1">CLDN2 Claudin-2</td><td valign="top" align="left" rowspan="1" colspan="1">2.43</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1"><bold>E, Transcriptional factors</bold></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GenBank accession no.</td><td valign="top" align="left" rowspan="1" colspan="1">Gene name</td><td valign="top" align="left" rowspan="1" colspan="1">Gene full name</td><td valign="top" align="left" rowspan="1" colspan="1">Fold upregulation</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC070398</td><td valign="top" align="left" rowspan="1" colspan="1">PPAR&#x003b4;</td><td valign="top" align="left" rowspan="1" colspan="1">Peroxisome proliferator activator receptor &#x003b4;</td><td valign="top" align="left" rowspan="1" colspan="1">2.00</td></tr></tbody></table></table-wrap><table-wrap id="tIV-ijmm-43-04-1789" orientation="portrait" position="float"><label>Table IV</label><caption><p>Downregulation of epidermal barrier-associated genes following treatment with all-<italic>trans</italic> retinoic acid in HaCaT cells (n=1 per group;-fold change &#x0003e;2; P&#x0003c;0.05).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4" valign="top" align="left" rowspan="1">A, Intermediate filament
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">GenBank accession no.</th><th valign="top" align="left" rowspan="1" colspan="1">Gene name</th><th valign="top" align="left" rowspan="1" colspan="1">Gene full name</th><th valign="top" align="left" rowspan="1" colspan="1">Fold downregulation</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_181619</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP21-1</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 21-1</td><td valign="top" align="left" rowspan="1" colspan="1">2.38</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_033448</td><td valign="top" align="left" rowspan="1" colspan="1">KRT71</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 71</td><td valign="top" align="left" rowspan="1" colspan="1">2.00</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC024292</td><td valign="top" align="left" rowspan="1" colspan="1">KRT5</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 5</td><td valign="top" align="left" rowspan="1" colspan="1">2.22</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1"><bold>B, Proteases and protease inhibitors</bold></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GenBank accession no.</td><td valign="top" align="left" rowspan="1" colspan="1">Gene name</td><td valign="top" align="left" rowspan="1" colspan="1">Gene full name</td><td valign="top" align="left" rowspan="1" colspan="1">Fold downregulation</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC069417</td><td valign="top" align="left" rowspan="1" colspan="1">SERPINB7</td><td valign="top" align="left" rowspan="1" colspan="1">Serpin family B member 7</td><td valign="top" align="left" rowspan="1" colspan="1">3.15</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_000185</td><td valign="top" align="left" rowspan="1" colspan="1">SERPIND1</td><td valign="top" align="left" rowspan="1" colspan="1">Serpin family D member 1</td><td valign="top" align="left" rowspan="1" colspan="1">2.36</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_007173</td><td valign="top" align="left" rowspan="1" colspan="1">PRSS23</td><td valign="top" align="left" rowspan="1" colspan="1">Serine protease 23</td><td valign="top" align="left" rowspan="1" colspan="1">4.13</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_022046</td><td valign="top" align="left" rowspan="1" colspan="1">KLK14</td><td valign="top" align="left" rowspan="1" colspan="1">Kallikrein related peptidase 10</td><td valign="top" align="left" rowspan="1" colspan="1">2.29</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1"><bold>C, Tight junction</bold></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GenBank accession no.</td><td valign="top" align="left" rowspan="1" colspan="1">Gene name</td><td valign="top" align="left" rowspan="1" colspan="1">Gene full name</td><td valign="top" align="left" rowspan="1" colspan="1">Fold downregulation</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AK128686</td><td valign="top" align="left" rowspan="1" colspan="1">PDZD2</td><td valign="top" align="left" rowspan="1" colspan="1">PDZ domain containing 2</td><td valign="top" align="left" rowspan="1" colspan="1">2.15</td></tr></tbody></table></table-wrap><table-wrap id="tV-ijmm-43-04-1789" orientation="portrait" position="float"><label>Table V</label><caption><p>Upregulation of epidermal barrier-associated genes following treatment with all-<italic>trans</italic> retinoic acid in HaCaT cells (n=1 per group;-fold change &#x0003e;2; P&#x0003c;0.05).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4" valign="top" align="left" rowspan="1">A, Intermediate filament
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1"> GenBank accession no.</th><th valign="top" align="left" rowspan="1" colspan="1">Gene name</th><th valign="top" align="left" rowspan="1" colspan="1">Gene full name</th><th valign="top" align="left" rowspan="1" colspan="1">Fold upregulation</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_002275</td><td valign="top" align="left" rowspan="1" colspan="1">KRT15</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 15</td><td valign="top" align="left" rowspan="1" colspan="1">2.07</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC072018</td><td valign="top" align="left" rowspan="1" colspan="1">KRT17</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin 17</td><td valign="top" align="left" rowspan="1" colspan="1">2.68</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AB096945</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP19-4</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 19-4</td><td valign="top" align="left" rowspan="1" colspan="1">2.07</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC101555</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP7-1</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 7-1 (gene/pseudogene)</td><td valign="top" align="left" rowspan="1" colspan="1">2.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_032524</td><td valign="top" align="left" rowspan="1" colspan="1">KRTAP4-4</td><td valign="top" align="left" rowspan="1" colspan="1">Keratin associated protein 4-4</td><td valign="top" align="left" rowspan="1" colspan="1">2.16</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1"><bold>B, Proteases and protease inhibitors</bold></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GenBank accession no.</td><td valign="top" align="left" rowspan="1" colspan="1">Gene name</td><td valign="top" align="left" rowspan="1" colspan="1">Gene full name</td><td valign="top" align="left" rowspan="1" colspan="1">Fold upregulation</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_001085</td><td valign="top" align="left" rowspan="1" colspan="1">SERPINA3</td><td valign="top" align="left" rowspan="1" colspan="1">Serpin family A member 3</td><td valign="top" align="left" rowspan="1" colspan="1">12.30</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_000624</td><td valign="top" align="left" rowspan="1" colspan="1">SERPINA5</td><td valign="top" align="left" rowspan="1" colspan="1">Serpin family A member 5</td><td valign="top" align="left" rowspan="1" colspan="1">2.03</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC034528</td><td valign="top" align="left" rowspan="1" colspan="1">SERPINB8</td><td valign="top" align="left" rowspan="1" colspan="1">Serpin family B member 8</td><td valign="top" align="left" rowspan="1" colspan="1">2.11</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_000934</td><td valign="top" align="left" rowspan="1" colspan="1">SERPINF2</td><td valign="top" align="left" rowspan="1" colspan="1">Serpin family F member 2</td><td valign="top" align="left" rowspan="1" colspan="1">2.06</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_002575</td><td valign="top" align="left" rowspan="1" colspan="1">SERPINB2</td><td valign="top" align="left" rowspan="1" colspan="1">Serpin family B member 2</td><td valign="top" align="left" rowspan="1" colspan="1">2.17</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC009726</td><td valign="top" align="left" rowspan="1" colspan="1">PRSS22</td><td valign="top" align="left" rowspan="1" colspan="1">Serine protease 22</td><td valign="top" align="left" rowspan="1" colspan="1">4.26</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AF335478</td><td valign="top" align="left" rowspan="1" colspan="1">KLK3</td><td valign="top" align="left" rowspan="1" colspan="1">Kallikrein related peptidase 3</td><td valign="top" align="left" rowspan="1" colspan="1">2.27</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_001012964</td><td valign="top" align="left" rowspan="1" colspan="1">KLK6</td><td valign="top" align="left" rowspan="1" colspan="1">Kallikrein related peptidase 6</td><td valign="top" align="left" rowspan="1" colspan="1">2.95</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_002776</td><td valign="top" align="left" rowspan="1" colspan="1">KLK10</td><td valign="top" align="left" rowspan="1" colspan="1">Kallikrein related peptidase 10</td><td valign="top" align="left" rowspan="1" colspan="1">2.44</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_006853</td><td valign="top" align="left" rowspan="1" colspan="1">KLK11</td><td valign="top" align="left" rowspan="1" colspan="1">Kallikrein related peptidase 11</td><td valign="top" align="left" rowspan="1" colspan="1">2.43</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_015596</td><td valign="top" align="left" rowspan="1" colspan="1">KLK13</td><td valign="top" align="left" rowspan="1" colspan="1">Kallikrein related peptidase 13</td><td valign="top" align="left" rowspan="1" colspan="1">2.80</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_017509</td><td valign="top" align="left" rowspan="1" colspan="1">KLK15</td><td valign="top" align="left" rowspan="1" colspan="1">Kallikrein related peptidase 15</td><td valign="top" align="left" rowspan="1" colspan="1">2.02</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1"><bold>C, Tight junction</bold></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GenBank accession no.</td><td valign="top" align="left" rowspan="1" colspan="1">Gene name</td><td valign="top" align="left" rowspan="1" colspan="1">Gene full name</td><td valign="top" align="left" rowspan="1" colspan="1">Fold upregulation</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BC029886</td><td valign="top" align="left" rowspan="1" colspan="1">OCLN Occludin</td><td valign="top" align="left" rowspan="1" colspan="1">2.63</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NM_001305</td><td valign="top" align="left" rowspan="1" colspan="1">CLDN4 Claudin-4</td><td valign="top" align="left" rowspan="1" colspan="1">2.02</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></floats-group></article>